WO2006065938A2 - Cancer-specific spanx-n markers - Google Patents
Cancer-specific spanx-n markers Download PDFInfo
- Publication number
- WO2006065938A2 WO2006065938A2 PCT/US2005/045317 US2005045317W WO2006065938A2 WO 2006065938 A2 WO2006065938 A2 WO 2006065938A2 US 2005045317 W US2005045317 W US 2005045317W WO 2006065938 A2 WO2006065938 A2 WO 2006065938A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- spanx
- seq
- nucleic acid
- sequence
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
Definitions
- the invention relates to SPANX-N genes, a new cluster of genes whose expression is detected in few normal adult tissues, with the highest expression in normal testis tissues. Some of the SPANX-N genes are also highly expressed in tumor tissues, including prostate, melanoma, uterine and cervical cancer tissues.
- the invention therefore provides SPANX nucleic acids, polypeptides and antibodies useful for detecting and treating prostate cancer.
- prostate cancer is the most common cancer, occu ⁇ ing in as many as 15% of men in the United States. Approximately 330,000 new cases are diagnosed annually. Prostate cancer kills about 40,000 men in the United States each year and is second only to lung cancer in mortality to men. Castration, treatment with anti-androgens, and prostatectomy with its associated urogenital risk, are all treatments that can seriously compromise the quality of life for men diagnosed too late for less drastic prostate cancer treatments. Hence, early detection and treatment is critical.
- PSA serum prostate-specific antigen
- level and prostate digital rectal exams are the only early diagnostic tests in routine use for screening for prostate cancer.
- small, aggressive tumors can be missed by digital rectal exams and even by needle biopsy, and only modest increases in prostate-specific antigen, i.e., below the 4 ng/mL threshold between normal and elevated PSA levels, are generated by these tumors.
- These aggressive tumors have the potential to suddenly dedifferentiate, grow, spread, and metastasize rapidly.
- the NCI Fact Sheet also indicates that a need exists for a prostate cancer screen with an improved ability to differentiate between prostate cancer and benign conditions such as prostatitis, benign prostatic hypertrophy (BPH), inflammation and infection.
- BPH benign prostatic hypertrophy
- a need also exists for prostate cancer screens that can differentiate between slow-growing and fast-growing cancers.
- cancer of the cervix is one of the most common malignancies in women and remains a significant public health problem throughout the world.
- invasive cervical cancer accounts for approximately 19% of all gynecological cancers.
- it was estimated that there were 14,700 newly diagnosed cases and 4900 deaths attributed to this disease (American Cancer Society, Cancer Facts & Figures 1996, Atlanta, Ga.: American Cancer Society, 1996).
- the clinical problem is more serious.
- the number of new cases is estimated to be 471,000 with a four-year survival rate of only 40% (Munoz et al., 1989, Epidemiology of
- Cervical cancer is detected by cellular diagnosis conducted by scrubbing a cervical surface with a cotton swab or a scrubber, immediately smearing the scrubbed cells on a slide glass to prepare a sample and observing the sample under a microscope or the like. The diagnosis is then performed by observing the form of the cells under a microscope and involves examination of each sample by a cytotechnologist. Therefore, a need exists for improved accuracy and speed in processing samples so that cervical cancer can be detected and treated before malignancy develops.
- the invention provides polypeptides and nucleic acids that are expressed in cancer cells and that can act as cancer markers.
- one aspect of the invention is an isolated polypeptide having an amino acid sequence corresponding to any one of SEQ ID NO: 1-5.
- the isolated polypeptide is a SPANX-Nl polypeptide with SEQ ID NO:1.
- nucleic acid encoding a polypeptide having an amino acid sequence corresponding to any one of SEQ ID NO: 1-5.
- nucleic acid encodes an isolated SPANX-Nl polypeptide with SEQ ID NO: 1.
- Another aspect of the invention is an isolated nucleic acid comprising a SPANX-N promoter that includes one of the following nucleotide sequences SEQ ID NO:206-210.
- the promoter is a SPANX-Nl promoter (SEQ ID NO:206), which can promote expression in a variety of cancer cells and tumor tissue types.
- Another aspect of the invention is an expression cassette that includes a nucleic acid encoding a therapeutic gene product operably linked to a SPANX-N promoter of the invention.
- Another aspect of the invention is an isolated antibody that can bind to a polypeptide having an amino acid sequence corresponding to any one of SEQ ID NO.1-5.
- the antibody can bind to a SPANX-N peptide consisting essentially of any one of SEQ ID NO: 12-25, or 136.
- Another aspect of the invention is an isolated SPANX-N-specific nucleic acid.
- the invention provides a SP ANX-N- specific probe or primer with any one of SEQ ID NO:37, 38, 145-176.
- the isolated SPANX-N primer or probe has any one of SEQ ID NO: 145-152.
- the invention provides SPANX-N nucleic acids with any one of SEQ ID NO:26-30.
- nucleic acids that can inhibit the function of a SPANX mRNA include DNA or RNA molecules that can hybridize to a nucleic acid encoding a SPANX-N polypeptide having an amino acid sequence comprising any one of SEQ ID NO: 1-5.
- the nucleic acid can be a small interfering RNA (siRNA), ribozyme, or antisense nucleic acid.
- siRNA that consists essentially of a double-stranded RNA with any one of SEQ ID NO:39-61.
- Another aspect of the invention is a method for detecting cancer that involves contacting a non-testis tissue sample with a SPANX-N probe and observing whether an mRNA or cDNA in the sample hybridizes to the SPANX- N probe; wherein the SPANX-N probe comprises any one of SEQ ID NO:26-30, 37, 38, 145-176, or a combination thereof.
- Another aspect of the invention involves a method for detecting cancer comprising performing nucleic acid amplification of RNA from a non-testis tissue sample using SPANX-N primers consisting essentially of SEQ ID NO:37 and 38, and observing whether a SPANX-N nucleic acid fragment is amplified.
- the SPANX-N nucleic acid fragment can be about 240 to about 290 base pairs in length, or about 260-270 base pairs in length.
- Another aspect of the invention involves a method for detecting cancer comprising performing nucleic acid amplification of RNA from a non-testis tissue sample using SPANX-Nl primers consisting essentially of SEQ ID NO: 1
- Another aspect of the invention involves a method for detecting cancer comprising contacting a non-testis tissue sample with an anti-SPANX-N antibody and observing whether a complex forms between the antibody and a SPANX-N polypeptide.
- the SPANX-N polypeptide can have any one of SEQ ID NO: 1-5.
- the antibody can bind to any SPANX-N peptidyl epitope.
- the peptide epitope is a SPANX-N epitope that includes SEQ ID NO: 136.
- Another aspect of the invention is a method for treating cancer in a mammal comprising administering to the mammal an effective amount of an antibody that can bind to a SPANX-N peptide consisting of SEQ ID NO: 136.
- Another aspect of the invention is a method for treating cancer in a mammal comprising administering to the mammal an effective amount of a nucleic acid that encodes an anti-cancer agent operably linked to a SPANX-Nl promoter comprising SEQ ID NO:206.
- the anti-cancer agent can, for example, be a cytokine, interferon, hormones, cell growth inhibitor, cell cycle regulator, apoptosis regulator, cytotoxin, cytolytic viral product, or antibody.
- Another aspect of the invention involves a method for treating cancer comprising administering to a mammal an effective amount of a nucleic acid that can inhibit the function of a SPANX-N mRNA, wherein the nucleic acid comprises a DNA or RNA that can hybridize to a mRNA encoding a SPANX-N polypeptide having an amino acid sequence comprising any one of SEQ ID NO: 1-5.
- the SPANX-N mRNA can be complementary to any one of SEQ ID NO-.26-30.
- the nucleic acid can be a small interfering RNA
- Another aspect of the invention is a method to identify an agent that modulates SPANX-N expression. This method involves contacting a test cell with a candidate agent and determining if the candidate agent increases or decreases expression of an SPANX-N gene in the test cell when compared to expression of the SPANX-N gene in a control cell that was not contacted with the candidate agent. The agent can increase or decrease SPANX-N expression.
- FIG. 1 illustrates the sizes of DNA fragments from the SPANX family from chimpanzee (African great apes), orangutan (great apes), rhesus macaque (Old World monkeys), and tamarin (New World monkeys), which can be amplified by polymerase chain reaction. Oligonucleotide primers were designed to be complementary to sequences within the promoter and 3' non-coding regions. The double upper bands for rhesus macaque and tamarin are presumably due to polymorphism in paralogs.
- FIG. 2 schematically illustrates the location of the SPANX family genes on human chromosome X.
- SPANX-Nl positions 142995930-143005820
- SPANX-N2 positions 141495326-141490625
- SPANX-N3 positions 141297635- 141291834)
- SPANX-N4 positions 140806882-140816198
- SPANX-N5 positions 51791606-51793934
- SPANX genes reside within large segmental duplications across the chromosome., where each duplication is homologous to the others.
- FIG. 3A-B are images of gels illustrating SPANX-N gene expression in human and mouse normal tissues as detected by reverse transcription- polymerase chain reaction (RT-PCR).
- FIG. 3A shows the cDNA prepared from a panel of human tissue mRNAs. Oligonucleotide primers employed were from exons 1 and 2 of the genomic sequence and designed to amplify putative transcripts. A 264-bp band of the expected size was observed only in testis. Two members of the human SPANX-N subfamily, SPANX-N2 and SPANX -N3, were detected upon cloning and sequencing of PCR products.
- FIG. 3B illustrates cDNA bands prepared from a panel of mouse tissue mRNAs.
- Oligonucleotide primers employed were from exons 1 and 2 of the genomic sequence and designed to amplify a putative transcript. A 264-bp band of the expected size was observed only in testis. Control PCR assays were carried out with the same samples by using actin-specific primers.
- FIG. 4A is a schematic diagram illustrating a hypothetical evolutionary tree for the SPANX gene family. The expansion of SPANX genes is superimposed on the tree of primate evolution.
- FIG. 4B provides a schematic diagram of the genomic changes that may have occurred during evolution of the different SPANX genes.
- FIG. 5 provides a neighbor-joining tree of primate SPANX genes. Noncoding regions (5' flanking regions and introns) were used for the tree reconstruction. The numbers at the interior branches indicate the percentage of 5,000 bootstrap pseudo-replicates that support the respective fork.
- FIG. 6A-B provides analyses of the affinity-purified anti-EQPT antibodies prepared against peptide sequence EQPTS STNGEKRKSPCESNN (positions 2-21, SEQ ID NO: 136) from the SPANX-N sequence.
- recombinant SPANX proteins were expressed in the pMAL-p2X bacterial expression vector. The proteins were purified as fusions with MBP by affinity chromatography. Lane 1 contained SPANX-N2 (uninduced) proteins. Lane 2 contained SPANX-N2 (induced) proteins. Lane 3 contained SPANX-B (induced) proteins. Lane 4 contained SPANX-C (induced) proteins. Lane 5 contained a 10-20OkDa ladder of molecular weight markers.
- Lane 6 contained SPANX-B purified proteins. Lane 7 contained SPANX-C purified proteins. Lane 8 contained SPANX-N2 purified (5ul) proteins. Lane 9 contained SPANX-N2 purified (lOul) proteins.
- FIG. 6B after separation of the recombinant proteins by SDS-PAGE, the gel was immunoblotted using anti- SPANX-N (EQPT) (lanes 1 , 2 and 3) antibodies. The antibodies exhibit a high specificity for the SPANX-N protein (lane 3).
- FIG. 7A-C illustrates expression of SPANX-N genes in normal and cancer tissues.
- SPANX-N expression was determined in normal tissues (FIG. 7A), in primary uterine tumors and melanoma cell lines (FIG. 7B), and in normal and tumor pairs (FIG. 7C).
- FOG. 7A normal tissues
- FIG. 7B primary uterine tumors and melanoma cell lines
- FIG. 7C normal and tumor pairs
- SPANX-Nl bars are horizontally (-) cross- hatched
- SPANX-N2 bars are diagonally (/) cross-hatched
- SPANX-N3 bars are vertically (
- SPANX-N4 bars are diagonally ( ⁇ ) cross-hatched
- SPANX-N5 bars are double cross-hatched (x).
- FIG. 8A-B provides a comparison of human SPANX- A/D and SPANX- N promoter sequences.
- the detected transcription start sites and the translation initiation codons (ATG) are indicated. Noncoding sequences are in lowercase.
- SPANX-N copies differ from SP ANX- A/D genes by the almost complete lack of all CpG dinucleotides in the promoter regions (CG above sequences). However, these CpGs are perfectly preserved in all of the SP ANX- A/D copies. Another difference is the presence of the SpI binding consensus in four SPANX-N copies.
- the invention relates to nucleic acids, polypeptides and antibodies useful for detecting cancer.
- the invention also provides nucleic acids that can modulate the function of SPANX mRNA transcripts and antibodies that can modulate the function of SPANX gene products.
- the invention relates to SPANX-N promoters that can express gene products in a tissue-specific manner, for example, in cancer cells where the promoter is generally active.
- nucleic acid refers to deoxyribonucleotides or ribonucleotides and polymers thereof in either single- or double-stranded form, composed of monomers (nucleotides) containing a sugar, phosphate and a base that is either a purine or pyrimidine. Unless specifically limited, the term encompasses nucleic acids containing known analogs of natural nucleotides that have similar binding properties as the reference nucleic acid and are metabolized in a manner similar to naturally occurring nucleotides.
- nucleic acid sequence also encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions) and complementary sequences, as well as the sequence explicitly indicated.
- degenerate codon substitutions may be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and/or deoxyinosine residues (Batzer et a!., Nucl. Acids Res..19. 508 (1991); Ohtsuka et al, JBC. 260. 2605 (1985); Rossolini et a!., MoI. Cell. Probes. 8, 91 (1994)).
- nucleic acid refers to any nucleic acid molecule.
- nucleic acid fragment is a portion of a given nucleic acid molecule.
- DNA in the majority of organisms is the genetic material while ribonucleic acid (RNA) is involved in the transfer of information contained within DNA into proteins.
- the invention encompasses isolated or substantially purified nucleic acid, peptide or polypeptide compositions.
- an "isolated” or “purified” DNA molecule or RNA molecule or an “isolated” or “purified” polypeptide is a DNA molecule, RNA molecule, or polypeptide that exists apart from its native environment and is therefore not a product of nature.
- An isolated DNA molecule, RNA molecule or polypeptide may exist in a purified form or may exist in a non-native environment such as, for example, a transgenic host cell.
- an "isolated” or “purified” nucleic acid molecule or protein, or biologically active portion thereof is substantially free of other cellular material, or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized.
- an "isolated" nucleic acid is free of sequences that naturally flank the nucleic acid (i.e., sequences located at the 5' and 3' ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived.
- the isolated nucleic acid molecule can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb, or 0.1 kb of nucleotide sequences that naturally flank the nucleic acid molecule in genomic DNA of the cell from which the nucleic acid is derived.
- a protein that is substantially free of cellular material includes preparations of protein or polypeptide having less than about 30%, 20%, 10%, or 5% (by dry weight) of contaminating protein.
- culture medium represents less than about 30%, 20%, 10%, or 5% (by dry weight) of chemical precursors or non-protein-of-interest chemicals.
- Fragments and variants of the disclosed nucleotide sequences and proteins or partial-length proteins encoded thereby are also encompassed by the present invention.
- fragment or portion is meant a full length or less than full length of the nucleotide sequence encoding, or the amino acid sequence of, a polypeptide or protein.
- genes include coding sequences and/or the regulatory sequences required for their expression.
- gene refers to a nucleic acid fragment that expresses mRNA, functional RNA, or specific protein, including regulatory sequences.
- Genes also include non- expressed DNA segments that, for example, form recognition sequences for other proteins.
- Genes can be obtained from a variety of sources, including cloning from a source of interest or synthesizing from known or predicted sequence information, and may include sequences designed to have desired parameters.
- Naturally occurring is used to describe an object that can be found in nature as distinct from being artificially produced.
- a protein or nucleotide sequence present in an organism including a virus, which can be isolated from a source in nature and which has not been intentionally modified by a person in the laboratory, is naturally occurring.
- protein protein
- variants are a sequence that is substantially similar to the sequence of the native molecule.
- variants include those sequences that, because of the degeneracy of the genetic code, encode the identical amino acid sequence of the native protein.
- Naturally occurring allelic variants such as these can be identified with the use of molecular biology techniques, as, for example, with polymerase chain reaction (PCR) and hybridization techniques.
- variant nucleotide sequences also include synthetically derived nucleotide sequences, such as those generated, for example, by using site-directed mutagenesis, which encode the native protein, as well as those that encode a polypeptide having amino acid substitutions.
- nucleotide sequence variants of the invention will have at least 40%, 50%, 60%, to 70%, e.g., 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, to 79%, generally at least 80%, e.g., 81%-84%, at least 85%, e.g., 86%, S7%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, to 9S%, sequence identity to the native (endogenous) nucleotide sequence.
- Consatively modified variations of a particular nucleic acid sequence refers to those nucleic acid sequences that encode identical or essentially identical amino acid sequences. Because of the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode any given polypeptide. For instance, the codons CGT, CGC, CGA, CGG, AGA and AGG all encode the amino acid arginine. Thus, at every position where an arginine is specified by a codon, the codon can be altered to any of the corresponding codons described without altering the encoded protein.
- nucleic acid variations are "silent variations,” which are one species of “conservatively modified variations.” Every nucleic acid sequence described herein that encodes a polypeptide also describes every possible silent variation, except where otherwise noted.
- each codon in a nucleic acid except ATG, which is ordinarily the only codon for methionine
- each "silent variation" of a nucleic acid that encodes a polypeptide is implicit in each described sequence.
- the invention contemplates SPANX-N polypeptides and peptides.
- Such polypeptides and peptides have utility, for example, for generating SPANX-N-specific antibodies.
- Such antibodies can be used for detecting, diagnosing and treating cancer.
- the invention provides a human SPANX-Nl polypeptide of the following sequence (SEQ ID NO:1).
- the invention provides a human SPANX-N2 polypeptide of the following sequence (SEQ ID NO:2).
- the invention provides a human SPANX-N3 polypeptide of the following sequence (SEQ ID NO:3).
- SEQ ID NO:3 1 MEQPTSSTNG EKTKSPCESN NKKNDEMQEV PNRVLAPEQS 41 LKKTKTSEYP IIFVYYLRKG KKINSNQLEN EQSQENSINP 81 IQKEEDEGVD LSEGSSNEDE DLGPCEGPSK EDKDLDSSEG 121 SSQEDEDLGL SEGSSQDSGE D
- the invention provides a human SPANX-N4 polypeptide of the following sequence (SEQ ID NO:4).
- the invention provides a human SPANX-N5 polypeptide of the following sequence (SEQ ID NO:5).
- the SPANX-N polypeptides of the invention have about 50% amino acid sequence identity with the SPANX- A/D proteins. Hence, they are structurally distinct and can readily be used to generate SP ANX-N- specific antibodies. Sequences for various SPANX- A/D polypeptides and nucleic acids are publicly available through the National Center for Biotechnology Information (http:/ ⁇ vww.ncbi.nlm.nih.gov/). For example, a sequence for a human SPANX- Al polypeptide can be found in the NCBI database at accession number NP 038481.2 (gi: 14192937). This sequence for human SPANX-Al has the following sequence (SEQ ID NO:6):
- SPANX- A2 polypeptide sequence is as follows (SEQ ID NO:7):
- SPANX-Bl A sequence for the human SPANX-Bl polypeptide can be found in the NCBI database at accession number NP 115850.1 (gi:14196344). This sequence for SPANX-Bl is as follows (SEQ ID NO:8):
- SPANX-C polypeptide A sequence for the human SPANX-C polypeptide can be found in the NCBI database at accession number NP 073152.1 (gi:13435137). This SPANX- C polypeptide has the following sequence (SEQ ID NO: 10):
- SPANX-D polypeptide A sequence for the human SPANX-D polypeptide can be found in the NCBI database at accession number NP 115793.1 (gi:14192939). This SPANX-D polypeptide has the following sequence (SEQ ID NO: 11 ):
- sequence identity or “identity” in the context of two nucleic acid or polypeptide sequences refers to a specified percentage of residues in the two sequences that are the same when the sequences are aligned for maximum correspondence over a specified comparison window, as measured by sequence comparison algorithms or by visual inspection.
- substantially identical in the context of a polypeptide or peptide indicates that a polypeptide or peptide comprises a sequence with at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, or 79%, preferably 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, S8%, or 89%, more preferably at least 90%, 91%, 92%, 93%, or 94%, or even more preferably, 95%, 96%, 97%, 98% or 99%, sequence identity to the reference sequence over a specified comparison window.
- optimal alignment is conducted using the homology alignment algorithm of Needleman and Wunsch (JMB, 48, 443 (1970)).
- a peptide is substantially identical to a second peptide, for example, where the two peptides differ only by a conservative substitution.
- the invention also contemplates variant SPANX-N polypeptides and peptides as well as SPANX-N polypeptides and peptides from mammalian species other than humans. Such SPANX-N polypeptides and peptides are useful for raising antibodies and for detecting cancer in mammalian species.
- Residue positions in variant polypeptides and peptides may not be identical to those in the reference sequence but often differ, for example, by conservative amino acid substitutions, where amino acid residues are substituted for other amino acid residues with similar chemical properties (e.g., charge or hydrophobicity) and therefore do not change the functional properties of the molecule. Sequences that differ by such conservative substitutions are said to have "sequence similarity" or “similarity.” When sequences differ in conservative substitutions, the percent sequence identity may be adjusted upwards to correct for the conservative nature of the substitution. Means for making this adjustment are available to those of skill in the art. Typically this involves scoring a conservative substitution as a partial rather than a full mismatch, thereby increasing the percentage sequence identity.
- variant polypeptide is intended a polypeptide derived from the native protein by deletion (also called “truncation") or addition of one or more amino acids to the N-terminal and/or C-terminal end of the native protein; deletion or addition of one or more amino acids at one or more sites in the native protein; or substitution of one or more amino acids at one or more sites in the native protein.
- variants may result from, for example, genetic polymorphism, species variation or from human manipulation. Methods for such manipulations are generally known in the art.
- polypeptides of the invention may have sequence differences including amino acid substitutions, deletions, truncations, and insertions. Methods for such manipulations are generally known in the art.
- amino acid sequence variants of the polypeptides can be prepared by mutations in the DNA. Methods for mutagenesis and nucleotide sequence alterations are well known in the art. See, for example, Kunkel, Proc. Natl. Acad. Sci. USA. 82, 488 (1985); Kunkel et al, Meth. EnzvmoL 154. 367 (1987); U. S. Patent No. 4,873,192; Walker and Gaastra (1983), and the references cited therein.
- polypeptides of the invention encompass both naturally- occurring proteins as well as variations and modified forms thereof. Such variants will continue to possess the desired activity.
- the deletions, insertions, and substitutions of the polypeptide sequence encompassed herein are not expected to produce radical changes in the characteristics of the polypeptide. However, when it is difficult to predict the exact effect of the substitution, deletion, or insertion in advance of doing so, one skilled in the art will appreciate that the effect will be evaluated by routine screening assays.
- any of the entire SPANX-N 1-5 polypeptides can be used for generating antibodies.
- selected peptides from any of the SPANX-N polypeptides can be used for this purpose. These antibodies are useful for detecting and treating cancer.
- the following peptide (SEQ ID NO: 136) can be used to generate antibodies that specifically bind to each of the SPANX-N 1-5 polypeptides:
- EQPTSSTNGEKRKSPCESNN (SPANX-N amino acid positions 2-21).
- SPANX-Nl specific peptide epitope has the following sequence:
- SPANX-N2 specific peptide epitopes include those with the following peptidyl sequences:
- SPANX-N3 specific peptide epitopes include those with the following sequences:
- GEKT SEQ ID NO: 16
- PIIFV SEQ ID NO: 17
- SKEDKLSEGSS (SEQ ID NO: IS); NKKNDEMQEVPNRVL (SEQ ID NO: 19); and KTKTSEYPIIFVYYL (SEQ ID NO:20).
- SPANX-N4 specific peptide epitopes include those with the following sequences:
- ESNNLH SEQ ID N0:21
- DGGQ SEQ ID NO:22
- SPANX-N5 specific peptide epitopes include those with the following sequences: GEICRK (SEQ ID NO:23);
- LVLEPS SEQ ID NO:24
- STVLVLCY SEQ ID NO:25
- the entire SPANX-N polypeptides SEQ ID NO: 1-5) and/or any of peptide SEQ ID NO: 12-25, 136 can be used to immunize animals to obtain SPANX-N specific antibodies.
- the invention therefore provides antibodies made by available procedures that can bind SPANX-N peptides and/or polypeptides.
- the binding domains of such antibodies for example, the CDR regions of these antibodies, can be transferred into or utilized with any convenient binding entity backbone.
- Antibody molecules belong to a family of plasma proteins called immunoglobulins, whose basic building block, the immunoglobulin fold or domain, is used in various forms in many molecules of the immune system and other biological recognition systems.
- a standard antibody is a tetrameric structure consisting of two identical immunoglobulin heavy chains and two identical light chains and has a molecular weight of about 150,000 daltons.
- the heavy and light chains of an antibody consist of different domains. Each light chain has one variable domain (VL) and one constant domain (CL), while each heavy chain has one variable domain (VH) and three or four constant domains (CH). See, e.g., Alzari, P. N., Lascombe, M.-B. & Poljak, R. J. (1988) Three-dimensional structure of antibodies. Annu. Rev. Immunol. 6, 555-580. Each domain, consisting of about 110 amino acid residues, is folded into a characteristic ⁇ -sandwich structure formed from two ⁇ -sheets packed against each other, the immunoglobulin fold.
- VH and VL domains each have three complementarity determining regions (CDRl -3) that are loops, or turns, connecting ⁇ -strands at " one end of the domains.
- CDRl -3 complementarity determining regions
- the variable regions of both the light and heavy chains generally contribute to antigen specificity, although the contribution of the individual chains to specificity is not always equal.
- Antibody molecules have evolved to bind to a large number of molecules by using six randomized loops (CDRs).
- Immunoglobulins can be assigned to different classes depending on the amino acid sequences of the constant domain of their heavy chains. There are at least five (5) major classes of immunoglobulins: IgA, IgD, IgE, IgG and IgM. Several of these may be further divided into subclasses (isotypes), for example, IgG-I, IgG-2, IgG-3 and IgG-4; IgA-I and IgA-2.
- the heavy chain constant domains that correspond to the IgA, IgD, IgE, IgG and IgM classes of immunoglobulins are called alpha ( ⁇ ), delta ( ⁇ ), epsilon ( ⁇ ), gamma ( ⁇ ) and mu ( ⁇ ), respectively.
- the light chains of antibodies can be assigned to one of two clearly distinct types, called kappa (K) and lambda ( ⁇ ), based on the amino sequences of their constant domain.
- K kappa
- ⁇ lambda
- the subunit structures and three- dimensional configurations of different classes of immunoglobulins are well known.
- variable in the context of variable domain of antibodies, refers to the fact that certain portions of variable domains differ extensively in sequence from one antibody to the next.
- the variable domains are for binding and determine the specificity of each particular antibody for its particular antigen.
- the variability is not evenly distributed through the variable domains of antibodies. Instead, the variability is concentrated in three segments called complementarity determining regions (CDRs), also known as hypervariable regions in both the light chain and the heavy chain variable domains.
- CDRs complementarity determining regions
- variable domains The more highly conserved portions of variable domains are called framework (FR) regions.
- the variable domains of native heavy and light chains each comprise four FR regions, largely adopting a ⁇ -sheet configuration, connected by three CDRs, which form loops connecting, and in some cases forming part of, the ⁇ -sheet structure.
- the CDRs in each chain are held together in close proximity by the FR regions and, with the CDRs from another chain, contribute to the formation of the antigen-binding site of antibodies.
- the constant domains are not involved directly in binding an antibody to an antigen, but exhibit various effector functions, such as participation of the antibody in antibody-dependent cellular toxicity.
- an antibody that is contemplated for use in the present invention thus can be in any of a variety of forms, including a whole immunoglobulin, an antibody fragment such as Fv, Fab, and similar fragments, a single chain antibody which includes the variable domain complementarity determining regions (CDR), and the like forms, all of which fall under the broad term "antibody”, as used herein.
- the present invention contemplates the use of any specificity of an antibody, polyclonal or monoclonal, and is not limited to antibodies that recognize and immunoreact with a specific SPANX-N polypeptide or derivative thereof.
- the binding regions, or CDR, of antibodies can be placed within the backbone of any convenient binding entity polypeptide.
- an antibody, binding entity or fragment thereof is used that is immunospecific for a SPANX-N polypeptide, as well as the variants and derivatives thereof.
- antibody fragment refers to a portion of a full-length antibody, generally the antigen binding or variable region.
- antibody fragments include Fab, Fab', F(ab') 2 and Fv fragments.
- Papain digestion of antibodies produces two identical antigen binding fragments, called Fab fragments, each with a single antigen binding site, and a residual Fc fragment.
- Fab fragments thus have an intact light chain and a portion of one heavy chain.
- Pepsin treatment yields an F(ab') 2 fragment that has two antigen binding fragments that are capable of cross-linking antigen, and a residual fragment that is termed a pFc' fragment.
- Fab' fragments are obtained after reduction of a pepsin digested antibody, and consist of an intact light chain and a portion of the heavy chain. Two Fab" fragments are obtained per antibody molecule. Fab 1 fragments differ from Fab fragments by the addition of a few residues at the carboxyl terminus of the heavy chain CHl domain including one or more cysteines from the antibody hinge region.
- Fv is the minimum antibody fragment that contains a complete antigen recognition and binding site. This region consists of a dimer of one heavy and one light chain variable domain in a tight, non-covalent association (V H -V L dimer). It is in this configuration that the three CDRs of each variable domain interact to define an antigen binding site on the surface of the VH -V L dimer.
- variable domain or half of an Fv comprising only three CDRs specific for an antigen
- functional fragment refers to Fv, F(ab) and F(ab') 2 fragments.
- Additional fragments can include diabodies, linear antibodies, single- chain antibody molecules, and multispecific antibodies formed from antibody fragments.
- Single chain antibodies are genetically engineered molecules containing the variable region of the light chain, the variable region of the heavy chain, linked by a suitable polypeptide linker as a genetically fused single chain molecule.
- Such single chain antibodies are also referred to as "single-chain Fv" or "sFv” antibody fragments.
- the Fv polypeptide further comprises a polypeptide linker between the VH and VL domains that enables the sFv to form the desired structure for antigen binding.
- diabodies refers to a small antibody fragments with two antigen-binding sites, where the fragments comprise a heavy chain variable domain (VH) connected to a light chain variable domain (VL) in the same polypeptide chain (VH-VL).
- VH heavy chain variable domain
- VL light chain variable domain
- VH-VL polypeptide chain
- Antibody fragments contemplated by the invention are therefore not full- length antibodies. However, such antibody fragments can have similar or improved immunological properties relative to a full-length antibody. Such antibody fragments may be as small as about 4 amino acids, 5 amino acids, 6 amino acids, 7 amino acids, 9 amino acids, about 12 amino acids, about 15 amino acids, about 17 amino acids, about 18 amino acids, about 20 amino acids, about 25 amino acids, about 30 amino acids or more.
- an antibody fragment of the invention can have any upper size limit so long as it is has similar or improved immunological properties relative to an antibody that binds with specificity to a SPANX-N polypeptide.
- smaller binding entities and light chain antibody fragments can have less than about 200 amino acids, less than about 175 amino acids, less than about 150 amino acids, or less than about 120 amino acids if the antibody fragment is related to a light chain antibody subunit.
- larger binding entities and heavy chain antibody fragments can have less than about 425 amino acids, less than about 400 amino acids, less than about 375 amino acids, less than about 350 amino acids, less than about 325 amino acids or less than about 300 amino acids if the antibody fragment is related to a heavy chain antibody subunit.
- Antibodies directed against a SPANX-N peptide or polypeptide can be made by any available procedure. Methods for the preparation of polyclonal antibodies are available to those skilled in the art. See, for example, Green, et al., Production of Polyclonal Antisera, in: Immunochemical Protocols (Manson, ed.), pages 1-5 (Humana Press); Coligan, et al., Production of Polyclonal Antisera in Rabbits, Rats Mice and Hamsters, in: Current Protocols in Immunology, section 2.4.1 (1992), which are hereby incorporated by reference. Monoclonal antibodies can also be employed in the invention. The term
- monoclonal antibody refers to an antibody obtained from a population of substantially homogeneous antibodies. In other words, the individual antibodies comprising the population are identical except for occasional naturally occurring mutations in some antibodies that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to polyclonal antibody preparations that typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, the monoclonal antibodies are advantageous in that they are synthesized by the hybridoma culture, uncoiitamiiiated by other immunoglobulins.
- the modifier "monoclonal” indicates that the antibody is obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method.
- the monoclonal antibodies herein specifically include "chimeric" antibodies in which a portion of the heavy and/or light chain is identical or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass. Fragments of such antibodies can also be used, so long as they exhibit the desired biological activity. See U.S. Patent No. 4,816,567; Morrison et al. Proc.
- Monoclonal antibodies can be isolated and purified from hybridoma cultures by a variety of well-established techniques. Such isolation techniques include affinity chromatography with Protein-A Sepharose, size-exclusion chromatography, and ion-exchange chromatography.
- the monoclonal antibodies to be used in accordance with the present invention may be made by the hybridoma method as described above or may be made by recombinant methods, e.g., as described in U.S. Pat. No. 4,816,567.
- Monoclonal antibodies for use with the present invention may also be isolated from phage antibody libraries using the techniques described in Clackson et al. Nature 352: 624-628 (1991), as well as in Marks et al., J. MoI Biol. 222: 581-597 (1991).
- Antibody fragments of the present invention can be prepared by proteolytic hydrolysis of the antibody or by expression of nucleic acids encoding the antibody fragment in a suitable host.
- Antibody fragments can be obtained by pepsin or papain digestion of whole antibodies conventional methods.
- antibody fragments can be produced by enzymatic cleavage of antibodies with pepsin to provide a 5S fragment described as F(ab') 2 .
- This fragment can be further cleaved using a thiol reducing agent, and optionally using a blocking group for the sulfhydryl groups resulting from cleavage of disulfide linkages, to produce 3.5S Fab' monovalent fragments.
- a thiol reducing agent optionally using a blocking group for the sulfhydryl groups resulting from cleavage of disulfide linkages, to produce 3.5S Fab' monovalent fragments.
- pepsin produces two monovalent Fab' fragments and an Fc fragment directly.
- Fv fragments comprise an association of VH and V L chains. This association may be noncovalent or the variable chains can be linked by an intermolecular disulfide bond or cross-linked by chemicals such as glutaraldehyde.
- the Fv fragments comprise VH and V L chains connected by a peptide linker.
- sFv single-chain antigen binding proteins
- CDR peptides (“minimal recognition units") are often involved in antigen recognition and binding.
- CDR peptides can be obtained by cloning or constructing genes encoding the CDR of an antibody of interest. Such genes are prepared, for example, by using the polymerase chain reaction to synthesize the variable region from RNA of antibody-producing cells. See, for example, Larrick, et al., Methods: a Companion to Methods in Enzymology, Vol. 2, page 106 (1991).
- humanized antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab') 2 or other antigen-binding subsequences of antibodies) that contain minimal sequence derived from non-human immunoglobulin.
- humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a nonhuman species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity.
- CDR complementary determining region
- humanized antibodies may comprise residues that are found neither in the recipient antibody nor in the imported CDR or framework sequences. These modifications are made to further refine and optimize antibody performance.
- humanized antibodies will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence.
- the humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin.
- Fc immunoglobulin constant region
- binding entities which comprise polypeptides that can recognize and bind to a SPANX-N polypeptide.
- a number of proteins can serve as protein scaffolds to which binding domains reactive with a SPANX-N peptide can be attached and thereby form a suitable binding entity.
- the binding domains bind or interact with a SPANX-N peptide while the protein scaffold merely holds and stabilizes the binding domains so that they can bind.
- a number of protein scaffolds can be used.
- phage capsid proteins can be used. See Review in Clackson & Wells, Trends Biotechnol. 12: 173- 184 (1994).
- Phage capsid proteins have been used as scaffolds for displaying random peptide sequences, including bovine pancreatic trypsin inhibitor (Roberts et al., PNAS 89:2429-2433 (1992)), human growth hormone (Lowman et al., Biochemistry 30:10S32-10S3S (1991)), Venturini et al., Protein Peptide Letters 1 :70-75 (1994)), and the IgG binding domain of Streptococcus (O'Neil et al., Techniques in Protein Chemistry V (Crabb, L,. ed.) pp. 517-524, Academic Press, San Diego (1994)). These scaffolds have displayed a single randomized loop or region that can be modified to include binding domains for a SPANX-N peptide or polypeptide.
- Tendamistat is a ⁇ -sheet protein from Streptomyces tendae. It has a number of features that make it an attractive scaffold for binding peptides, including its small size, stability, and the availability of high resolution NMR and X-ray structural data.
- the overall topology of Tendamistat is similar to that of an immunoglobulin domain, with two ⁇ -sheets connected by a series of loops.
- Tendamistat In contrast to immunoglobulin domains, the ⁇ -sheets of Tendamistat are held together with two rather than one disulfide bond, accounting for the considerable stability of the protein.
- the loops of Tendamistat can serve a similar function to the CDR loops found in immunoglobulins and can be easily randomized by in vitro mutagenesis.
- Tendamistat is derived from Streptomyces tendae and may be antigenic in humans.
- binding entities that employ Tendamistat are preferably employed in vitro.
- Fibronectin type III domain has also been used as a protein scaffold to which binding entities can be attached.
- Fibronectin type III is part of a large subfamily (Fn3 family or s-type Ig family) of the immunoglobulin superfamily. Sequences, vectors and cloning procedures for using such a fibronectin type III domain as a protein scaffold for binding entities (e.g. CDR peptides) are provided, for example, in U.S. Patent Application Publication 20020019517. See also, Bork, P. & Doolittle, R. F. (1992) Proposed acquisition of an animal protein domain by bacteria. Proc. Natl. Acad. Sci. USA 89, 8990-8994; Jones, E. Y.
- Variant binding entities, antibody fragments and antibodies therefore can also be generated through display-type technologies.
- display-type technologies include, for example, phage display, retroviral display, ribosomal display, and other techniques.
- Techniques available in the art can be used for generating libraries of binding entities, for screening those libraries and the selected binding entities can be subjected to additional maturation, such as affinity maturation.
- Wright and Harris, supra. Hanes and Plucthau PNAS USA 94:4937-4942 (1997) (ribosomal display), Parmley and Smith Gene 73:305-318 (1988) (phage display), Scott TIBS 17:241-245 (1992), Cwirla et al. PNAS USA 87:6378-6382 (1990), Russel et al.
- a mutant binding domain refers to an amino acid sequence variant of a selected binding domain (e.g. a CDR). In general, one or more of the amino acid residues in the mutant binding domain is different from what is present in the reference binding domain.
- Such mutant antibodies necessarily have less than 100% sequence identity or similarity with the reference amino acid sequence, hi general, mutant binding domains have at least 75% amino acid sequence identity or similarity with the amino acid sequence of the reference binding domain.
- mutant binding domains have at least 80%, more preferably at least 85%, even more preferably at least 90%, and most preferably at least 95% amino acid sequence identity or similarity with the amino acid sequence of the reference binding domain.
- affinity maturation using phage display can be utilized as one method for generating mutant binding domains.
- Affinity maturation using phage display refers to a process described in Lowman et al., Biochemistry 30(45): 10832-10838 (1991), see also Hawkins et al., J. MoI Biol. 254: 889-896 (1992).
- this process can be described briefly as involving mutation of several binding domains or antibody hypervariable regions at a number of different sites with the goal of generating all possible amino acid substitutions at each site.
- the binding domain mutants thus generated are displayed in a monovalent fashion from filamentous phage particles as fusion proteins. Fusions are generally made to the gene III product of Ml 3.
- the phage expressing the various mutants can be cycled through several rounds of selection for the trait of interest, e.g. binding affinity or selectivity.
- the mutants of interest are isolated and sequenced. Such methods are described in more detail in U.S. Patent 5,750,373, U.S. Patent 6,290,957 and Cunningham, B. C. et al., EMBO J. 13(11), 2508-2515 (1994).
- the invention provides methods of manipulating binding entity or antibody polypeptides or the nucleic acids encoding them to generate binding entities, antibodies and antibody fragments with improved binding properties that recognize a SPANX-N polypeptide.
- Such methods of mutating portions of an existing binding entity or antibody involve fusing a nucleic acid encoding a polypeptide that encodes a binding domain reactive with a SPANX-N peptide to a nucleic acid encoding a phage coat protein to generate a recombinant nucleic acid encoding a fusion protein, mutating the recombinant nucleic acid encoding the fusion protein to generate a mutant nucleic acid encoding a mutant fusion protein, expressing the mutant fusion protein on the surface of a phage, and selecting phage that bind to a SPANX-N polypeptide.
- the invention provides antibodies, antibody fragments, and binding entity polypeptides that can recognize and bind to a SPANX-N polypeptide.
- the invention further provides methods of manipulating those antibodies, antibody fragments, and binding entity polypeptides to optimize their binding properties or other desirable properties (e.g., stability, size, ease of use).
- Such antibodies, antibody fragments, and binding entity polypeptides can be modified to include a label or reporter molecule useful for detecting the presence of the antibody.
- the labeled antibody can then be used for detection of SPANX-N polypeptides.
- a label or reporter molecule is any molecule that can be associated with an antibody, directly or indirectly, and that results in a measurable, detectable signal, either directly or indirectly.
- labels can be incorporated into or coupled onto an antibody or binding entity are available to those of skill in the art.
- labels suitable for use with the antibodies and binding entities of the invention include radioactive isotopes, fluorescent molecules, phosphorescent molecules, enzymes, secondary antibodies, and ligands.
- fluorescent labels examples include fluorescein (FITC), 5,6- carboxymethyl fluorescein, Texas red, nitrobenz-2-oxa-l,3-diazol-4-yl (NBD), coumarin, dansyl chloride, rhodamine, 4'-6-diamidino-2-phenylinodole (DAPI), and the cyanine dyes Cy3, Cy3.5, Cy5, Cy5.5 and Cy7.
- the fluorescent label is fluorescein (5-carboxyfluorescein-N-hydroxysuccinimide ester) or rhodamine (5,6-tetramethyl rhodamine).
- Fluorescent labels for combinatorial multicolor used in some embodiments include FITC and the cyanine dyes Cy3, Cy3.5, Cy5, Cy5.5 and Cy7.
- the absoiption and emission maxima, respectively, for these fluors are: FITC (490 nm; 520 nm), Cy3 (554 nm; 568 nm), Cy3.5 (581 nm; 588 nm), Cy5 (652 nm: 672 nm), Cy5.5 (682 nm; 703 nm) and Cy7 (755 nm; 778 nm), thus allowing their simultaneous detection.
- fluorescent labels can be obtained from a variety of commercial sources, including Molecular Probes, Eugene. OR and Research Organics, Cleveland, Ohio.
- Biotin can be detected using streptavidin-alkaline phosphatase conjugate (Tropix., Inc.) that binds to the biotin and subsequently can be detected by chemiluminescence of suitable substrates (for example, the chemiluminescent substrate CSPD: disodium, 3-(4-methoxyspiro-[l,2, - dioxetane-3-2'-(5'-chloro)tricyclo [3.3.1.1.sup.3,7 ]decane]-4-yl) phenyl phosphate; Tropix, Inc.).
- suitable substrates for example, the chemiluminescent substrate CSPD: disodium, 3-(4-methoxyspiro-[l,2, - dioxetane-3-2'-(5'-chloro)tricyclo [3.3.1.1.sup.3,7 ]decane]-4-yl
- Molecules that combine two or more of these reporter molecules or detection labels can also be used in the invention. Any of the known detection labels can be used with the disclosed antibodies, antibody fragments, binding entities, and methods. Methods for detecting and measuring signals generated by detection labels are also available to those of skill in the art. For example, radioactive isotopes can be detected by scintillation counting or direct visualization; fluorescent molecules can be detected with fluorescent spectrophotometers; phosphorescent molecules can be detected with a scanner or spectrophotometer, or directly visualized with a camera; enzymes can be detected by visualization of the product of a reaction catalyzed by the enzyme. Such methods can be used directly in methods for detecting SPANX-N polypeptides.
- the invention provides SPANX-N nucleic acids that encode SPANX-N polypeptides and peptides.
- the invention provides SPANX-specific nucleic acids, probes and primers that can be used to detect tissues that express SPANX, for example, normal testis, cervical cancer, uterine cancer, melanoma and prostate cancer tissues.
- the invention provides SPANX-N promoters that can be used to express desirable gene products in a tissue-specific manner.
- the SPAN-Nl promoter is active in a variety of cancer cells.
- the invention relates to SPANX-specific nucleic acids that can modulate or inhibit the function of a SPANX mRNA.
- the SPANX-specific nucleic acids that can modulate or inhibit the function of a SPANX mRNA are useful for treating cancer.
- the invention provides nucleic acids that encode SPANX-N polypeptides.
- the SPANX-Nl polypeptide having SEQ ID NO:1 is encoded by the cDNA sequence provided below (SEQ ID NO:26):
- SPANX-N2 polypeptide having SEQ ID NO:2 is encoded by the cDNA sequence provided below (SEQ ID NO:27):
- SPANX-N3 polypeptide having SEQ ID NO:3 is encoded by the cDNA sequence provided below (SEQ ID NO:28):
- SPANX-N4 polypeptide having SEQ ID NO:4 is encoded by the cDNA sequence provided below (SEQ ID NO.29):
- SPANX-N5 polypeptide having SEQ ID NO: 5 is encoded by the cDNA sequence provided below (SEQ ID NO:30):
- SPANX-Al polypeptide having SEQ ID NO:6 is encoded by the cDNA sequence provided below (SEQ ID NO:31):
- SPANX- A2 polypeptide having SEQ ID NO: 7 is encoded by the cDNA sequence provided below (SEQ ID NO:32):
- SPANX-Bl polypeptide having SEQ ID NO:8 is encoded by the cDNA sequence provided below (SEQ ID NO:33): 1 GTCACCAGGA GGGTATGCAT AGGGAGGGCA AGAGCTCTGG
- SPANX-B2 polypeptide having SEQ ID NO: 9 is encoded by the cDNA sequence provided below (SEQ ID NO:34): 1 GTCACCAGGA GGGTATGCAT AGGGAGGGCA AGAGCTCTGG
- SPANX-C polypeptide having SEQ ID NO: 10 is encoded by the cDNA sequence provided below (SEQ ID NO:35):
- SPANX-D polypeptide having SEQ ID NO:11 is encoded by the cDNA sequence provided below (SEQ ID NO:36): 1 AAGCCTGCCG CTGACATTGA AGAACCAATA TATACAATGG
- the invention provides SPANX-N-specific nucleic acids, primers or probes.
- SPANX-N-specific nucleic acids, primers or probes can be used for detection of SPANX-N expression, for example, in testes and prostate cancer cells.
- expression of SPANX-N in non-testes tissues is an indication that such tissues are cancerous.
- any of the SPANX-N cDNAs (SEQ ID NO:26-30) provided above can serve as a SPANX-N-specific nucleic acid or probes.
- the invention also provides primers or probes that are referred to herein as the FhuS-F and RhuS-R primers, which specifically hybridize to the SPANX-N subfamily of genes. The sequences of these SPANX-N specific primers are shown below:
- FhuS-F 5'-atggaacagccgacttcaag-3' (SEQ ID NO:37)
- RhuS-R 5'-tgagtctaggccttcgtcct-3' (SEQ ID NO:38)
- the SEQ ID NO: 37-38 probes are specific for SPANX-N subfamily and distinguish these genes from SPANX-Al, -A2,-B,-C and-D genes subfamily. These primers were used for detecting SPANX-N expression and the products detected were confirmed to be SPANX-N nucleic acids by sequencing. In addition, the following probes can be used to detect SPANX-N transcripts and expression patterns. In addition, the following nucleic acids are useful for nucleic acid amplification of specific SPANX-N RNA and DNA sequences, including specific portions of SPANX-N RNA and DNA sequences. SPANX-Nl Exonl: Particularly useful for nucleic acid amplification (1,946 bp product)
- Nlexl-R 5'-acaactttcgttaaccgcca-3' SEQ ID NO:13S
- Exonl Particularly useful for nucleic acid sequencing
- Exon2 Particularly useful for nucleic acid amplification (1,779 bp) Nlex2-F 5'-agggaagtgaatacaccaga-3' (SEQ ID NO: 141)
- SeqN2ex2-F 5'-taacaggtgaccctacccat-3' (SEQ ID NO:143)
- SeqN2ex2-R 5'-gatcactggagaaggaggaa-3' SEQ ID NO: 1444
- SPANX-N2 Exonl Particularly useful for nucleic acid amplification (3,710 bp)
- N2ex2-F 5'-tgagcgagtactccagaga-3' (SEQ ID NO: 149)
- N2ex2-R 5'-ctggttgtgacgtactatact-3' (SEQ ID NO: 150)
- Exonl Particularly useful for nucleic acid amplification (4,593 bp) N3exl-F 5'-aggttcgcttggtttgttag-3' (SEQ ID NO: 153)
- N3exl-R 5'-acagcaactgaccaatcttc-3' (SEQ ID NO: 154)
- SPANX-N4 Exonl Particularly useful for nucleic acid amplification (1,515 bp)
- Exonl Particularly useful for nucleic acid sequencing
- SeqlN4 R 5'-tct gcaggtgtctgcagtat-3' (SEQ ID NO:164)
- SPANX-N1-5 Detecting SPANX-N expression in humans (e.g. by RT-PCR) spaxnl/n5-F (ISO bp) 5'-aagaggaagagcccctgtga-3' (SEQ ID NO:169) spaxnl/n5-R (180 bp) 5'-ggtcattctccagttgatttga-3' (SEQ ID NO:170)
- the SPANX-N promoter sequences can promote expression in selected cell and tissue types, including testis tissue, and in the case of the SPANX-Nl gene, in cancer cells.
- testis tissue and in the case of the SPANX-Nl gene, in cancer cells.
- SPANX-N4 transcripts were detected only in testis
- SPANX-N2-5 transcripts were detected in several normal nongametogenic tissues (placenta, prostate, proximal and distal colon, lung, and cervix), although the levels of this SPANX-N expression in these tissues was lower than that observed in testis (FIG. 7A and Table 10).
- SPANX-Nl was not expressed in normal, nongametogenic tissues. In other words, detectable levels of SPANX-Nl are not observed in normal tissues.
- the SPANX-Nl, SPANX-N2, SPANX-N3, SPANX-N4 and SPANX- N5 promoters have utility for expressing gene products in testis
- the SPANX-N2, SPANX-N3, SPANX-N4 and SPANX-N5 (but not SPANX-Nl) promoters have utility for expressing gene products in tissues such as placenta, prostate, proximal and distal colon, lung, and cervix.
- SPANX-Nl is not expressed in normal tissues (except testis and sperm), it is e ' xpressed in cancer cells.
- SPANX-Nl is a diagnostic marker for cancer.
- the SPANX-Nl promoter can be used to promote expression of anti-cancer gene products.
- the promoters of the SPANX-Nl through SPANX-N5 genes have the following sequences.
- SPANX-Nl Promoter SEQ ID NO:206
- SPANX-N2 Promoter SEQ ID NO:207
- SPANX-N4 Promoter (SEQ IDNO:209): 1 TCCATGTGAA CCATGAACAT TAAACATGGA GAAATGAGGA
- SPANX-N5 Promoter SEQ ID NO:210:
- genes, promoters and nucleotide sequences of the invention include both the naturally occurring sequences as well as variants thereof.
- the invention contemplates SPANX-N nucleic acids from mammalian species other than humans.
- sequence relationships between two or more nucleic acids or polynucleotides are used to describe the sequence relationships between two or more nucleic acids or polynucleotides: (a) “reference sequence,” (b) “comparison window,” (c) “sequence identity,” (d) “percentage of sequence identity,” and (e) “substantial identity”.
- reference sequence is a defined sequence used as a basis for sequence comparison.
- a reference sequence may be a subset or the entirety of a specified sequence; for example, as a segment of a full-length cDNA or gene sequence, or the complete cDNA or gene sequence.
- comparison window makes reference to a contiguous and specified segment of a polynucleotide sequence, wherein the polynucleotide sequence in the comparison window may comprise additions or deletions (i.e., gaps) compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences.
- the comparison window is at least 15 or 17 contiguous nucleotides in length, and optionally can be 20, 30, 40, 50, 100, or longer.
- Computer implementations of these mathematical algorithms can be utilized for comparison of sequences to determine sequence identity. Such implementations include, but are not limited to: CLUSTAL in the PC/Gene program (available from Intelligenetics, Mountain View, California); the ALIGN program (Version 2.0) and GAP, BESTFIT, BLAST, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Version 8 (available from Genetics Computer Group (GCG), 575 Science Drive, Madison, Wisconsin, USA). Alignments using these programs can be performed using the default parameters. Further information on the CLUSTAL program can be found in Higgins et al. , Gene, 73, 237 (1988); Higgins et al. CABIOS. 5. 151 (1989); Corpet et al, Nucl.
- HSPs high scoring sequence pairs
- Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always > 0) and N (penalty score for mismatching residues; always ⁇ 0).
- M forward score for a pair of matching residues
- N penalty score for mismatching residues; always ⁇ 0.
- a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when the cumulative alignment score falls off by the quantity X from its maximum achieved value, the cumulative score goes to zero or below due to the accumulation of one or more negative-scoring residue alignments, or the end of either sequence is reached.
- the BLAST algorithm In addition to calculating percent sequence identity, the BLAST algorithm also performs a statistical analysis of the similarity between two sequences.
- One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance.
- P(N) the smallest sum probability
- a test nucleic acid sequence is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid sequence to the reference nucleic acid sequence is less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.
- Gapped BLAST in BLAST 2.0
- PSI-BLAST in BLAST 2.0
- the default parameters of the respective programs e.g. BLASTN for nucleotide sequences, BLASTX for proteins
- W wordlength
- E expectation
- BLASTP program uses as defaults a wordlength (W) of 3, an expectation (E) of 10, and the BLOSUM62 scoring matrix. See website at ncbi.nlm.nih.gov. Alignment may also be performed manually by inspection.
- comparison of nucleotide sequences for determination of percent sequence identity to the promoter sequences disclosed herein is preferably made using the BlastN program (version 1.4.7 or later) with its default parameters or any equivalent program.
- equivalent program any sequence comparison program that, for any two sequences in question, generates an alignment having identical nucleotide or amino acid residue matches and an identical percent sequence identity when compared to the corresponding alignment generated by the preferred program.
- percentage of sequence identity means the value determined by comparing two optimally aligned sequences over a comparison window, wherein the portion of the polynucleotide sequence in the comparison window may comprise additions or deletions (i.e., gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences.
- the percentage is calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison, and multiplying the result by 100 to yield the percentage of sequence identity.
- substantially identical of polynucleotide sequences means that a polynucleotide comprises a sequence that has at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, or 79%, preferably at least 80%, 81%, S2%, 83%, 84%, 85%, 86%, 87%, 88%, or 89%, more preferably at least 90%, 91%, 92%, 93%, or 94%, and most preferably at least 95%, 96%, 97%, 9S%, or 99% sequence identity, compared to a reference sequence using one of the alignment programs described using standard parameters.
- amino acid sequences for these purposes normally means sequence identity of at least 70%, more preferably at least S0%, 90%, and most preferably at least 95%.
- nucleotide sequences are substantially identical if two molecules hybridize to each other under stringent conditions.
- stringent conditions are selected to be about 5 0 C lower than the thermal melting point (T n ,) for the specific sequence at a defined ionic strength and pH.
- stringent conditions encompass temperatures in the range of about I 0 C to about 20°C, depending upon the desired degree of stringency as otherwise qualified herein.
- Nucleic acids that do not hybridize to each other under stringent conditions are still substantially identical if the polypeptides they encode are substantially identical. This may occur, e.g., when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code.
- One indication that two nucleic acid sequences are substantially identical is when the polypeptide encoded by the first nucleic acid is immunologically cross reactive with the polypeptide encoded by the second nucleic acid.
- sequence comparison typically one sequence acts as a reference sequence to which test sequences are compared.
- test and reference sequences are input into a computer, subsequence coordinates are designated if necessary, and sequence algorithm program parameters are designated.
- sequence comparison algorithm then calculates the percent sequence identity for the test sequence(s) relative to the reference sequence, based on the designated program parameters.
- hybridizing specifically to refers to the binding, duplexing, or hybridizing of a molecule only to a particular nucleotide sequence under stringent conditions when that sequence is present in a complex mixture (e.g., total cellular) DNA or RNA.
- Bod(s) substantially refers to complementary hybridization between a probe nucleic acid and a target nucleic acid and embraces minor mismatches that can be accommodated by reducing the stringency of the hybridization media to achieve the desired detection of the target nucleic acid sequence.
- “Stringent hybridization conditions” and “stringent hybridization wash conditions” in the context of nucleic acid hybridization experiments such as Southern and Northern hybridizations are sequence dependent, and are different under different environmental parameters. Longer sequences hybridize specifically at higher temperatures.
- the T m is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. Specificity is typically the function of post- hybridization washes, the critical factors being the ionic strength and temperature of the final wash solution. For DNA-DNA hybrids, the T m can be approximated from the equation of Meinkoth and Wahl (Anal. Biochem.. 138.
- T m 81.5°C + 16.6 (log M) +0.41 (%GC) - 0.61 (% form) - 500/L; where M is the molarity of monovalent cations, %GC is the percentage of guanosine and cytosine nucleotides in the DNA, % form is the percentage of formamide in the hybridization solution, and L is the length of the hybrid in base pairs.
- T m is reduced by about I 0 C for each 1% of mismatching; thus, T m , hybridization, and/or wash conditions can be adjusted to hybridize to sequences of the desired identity. For example, if sequences with >90% identity are sought, the T m can be decreased 1O 0 C.
- stringent conditions are selected to be about 5 0 C lower than the thermal melting point (T m ) for the specific sequence and its complement at a defined ionic strength and pH.
- severely stringent conditions can utilize a hybridization and/or wash at 1, 2, 3, or 4°C lower than the thermal melting point (T m );
- moderately stringent conditions can utilize a hybridization and/or wash at 6, 7, 8, 9, or 10 0 C lower than the thermal melting point (T 1n );
- low stringency conditions can utilize a hybridization and/or wash at 11, 12, 13, 14, 15, or 20 0 C lower than the thermal melting point (T m ).
- An example of highly stringent wash conditions is 0.15 M NaCl at 72 0 C for about 15 minutes.
- An example of stringent wash conditions is a 0.2X SSC wash at 65 0 C for 15 minutes (see, Sambrook and Russell, infra, for a description of SSC buffer).
- a high stringency wash is preceded by a low stringency wash to remove background probe signal.
- An example medium stringency wash for a duplex of, e.g., more than 100 nucleotides is IX SSC at 45 °C for 15 minutes.
- An example low stringency wash for a duplex of, e.g., more than 100 nucleotides is 4-6X SSC at 40 0 C for 15 minutes.
- stringent conditions typically involve salt concentrations of less than about 1.5 M, more preferably about 0.01 to 1.0 M, Na ion concentration (or other salts) at pH 7.0 to 8.3, and the temperature is typically at least about 30°C and at least about 6O 0 C for long probes (e.g., >50 nucleotides).
- Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide.
- destabilizing agents such as formamide.
- a signal to noise ratio of 2X (or higher) than that observed for an unrelated probe in the particular hybridization assay indicates detection of a specific hybridization.
- Nucleic acids that do not hybridize to each other under stringent conditions are still substantially identical if the proteins that they encode are substantially identical. This occurs, e.g. , when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code.
- Very stringent conditions are selected to be equal to the T m for a particular probe.
- An example of stringent conditions for hybridization of complementary nucleic acids which have more than 100 complementary residues on a filter in a Southern or Northern blot is 50% formamide, e.g., hybridization in 50% formamide, 1 M NaCl, 1% SDS at 37°C, and a wash in 0.1 X SSC at 60 to 65°C.
- Exemplary moderate stringency conditions include hybridization in 40 to 45% formamide, 1.0 M NaCl, 1% SDS at 37 0 C, and a wash in 0.5X to IX SSC at 55 to 6O 0 C.
- the SPANX-Nl through SPANX-N5 promoter sequences of the invention can be used to promote expression of therapeutic gene products in a tissue- specific manner.
- the SPANX-Nl through SPANX-N5 promoters can be operably linked to nucleic acids that encode beneficial and/or therapeutic gene products to form expression cassettes and/or expression vectors useful for promoting expression of those beneficial and/or therapeutic gene products in tissues where the SPANX-Nl through SPANX-N5 promoters are active.
- Nucleic acids encoding beneficial and/or therapeutic gene products that can be operably linked to the promoters of the invention include any available nucleic acids selected by one of skill in the art.
- nucleic acids that encode beneficial and/or therapeutic gene products include cytokines, interferons, growth factors, hormones, cell growth inhibitors, cell cycle regulators, apoptosis regulators, cytotoxins, cytolytic viruses, antibodies and the like.
- the nucleic acid encodes interleukins and cytokines, such as interleukin 1 (IL-I), IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-IO, IL-11, IL- 12, IL- 13, IL- 14, IL-15, INF-alpha, INF-beta, INF- gamma, angiostatin, thrombospondin, endostatin, METH-I, METH-2, Flk2/Flt3 ligand, GM-CSF, G-CSF, M-CSF, and tumor necrosis factor (TNF).
- IL-I interleukin 1
- IL-2 interleukin-2
- IL-3 interleukin-4
- IL-5 IL-6
- IL-7 IL-8
- IL-9 IL-IO
- IL-11 interleukin-11
- IL- 12 IL- 13, IL- 14, IL-15
- Interferons are soluble proteins that originally were found to induce antiviral activity in target cells. IFNs are now known to inhibit cell division and modulate the immune response. IFN-alpha produces an overall response rate of 20% in advanced melanoma and is associated with a 42% improvement in the fraction of patients with high risk melanoma who are disease-free.
- the melanoma differentiation associated protein 7 may be encoded in the nucleic acids linked to the SPANX-N promoters of the invention.
- MDA7 was identified following treatment of melanoma cells with interferon- alpha and mezerin.
- Jiang and Fisher noted loss of proliferative ability and terminal differentiation (Jiang et al., Proc. Natl. Acad. Sci. USA, 93:9160-9165 (1996)).
- Jiang and Fisher developed a novel subtraction hybridization scheme in human melanoma cells and this resulted in the identification and cloning of a series of melanoma- differentiation-associated (MDA) genes implicated in growth-controlled differentiation and apoptosis.
- MDA melanoma- differentiation-associated
- One of the MDA genes identified, MDA7 was noted to be a novel gene and expression of this gene correlated with the induction of terminal differentiation in human melanoma cells (Jiang et al., 1996; Jiang et al., Oncogene, 11 :2477-2486 (1995)).
- the MDA7 gene was noted to be expressed at high levels in proliferating normal melanocytes, but the expression was decreased as disease progressed to metastatic disease.
- MDA7 Ther., 7:2051-2057 (2000); Saeki et al., Oncogene, 21 :4558-4566 (2002)).
- the MDA7 gene was recently mapped to chromosome Iq32, an area containing a cluster of genes associated with the IL-10 family of cytokines (Mhashilkar et al., MoI Med., 7:271-282 (2001)).
- MDA7 has now been classified as interleukin-24 and has been demonstrated to bind to the IL-20 and IL-22 receptors, and subsequently mediate cell signaling.
- the nucleic acids linked to the promoters of the invention encode a hormone.
- hormones or steroids can be used in the present invention: insulin, somatotropin, gonadotropin, ACTH, CGH, or gastrointestinal hormones such as secretin.
- therapeutic gene products encoded by nucleic acids linked to the promoters of the invention include plant-, fungus-, or bacteria-derived toxins such as ricin A-chain (Burbage, Leuk Res., 21(7):681- 690 (1997)), a ribosome inactivating protein, a-sarcin, aspergillin, restrictocin, a ribonuclease, diphtheria toxin A (Masuda et al., MoI. Cell. Biol., 17:2066-2075 (1997); Lidor, Am. J. Obstet. Gynecol., 177(3):579-585 (1997)), pertussis toxin A subunit, E.
- Chemokines also may be used in the nucleic acids linked to promoters of the present invention. Chemokines generally act as chemoattractants to recruit immune effector cells to the site of chemokine expression. It may be advantageous to express a particular chemokine gene in combination with, for example, a cytokine gene, to enhance the recruitment of other immune system components to the site of treatment. Such chemokines include RANTES, MCAF, MIPl -alpha, MIPl -beta, and IP-IO. The skilled artisan will recognize that certain cytokines are also known to have chemoattractant effects and could also be classified under the term chemokines.
- nucleic acids encoding cell cycle regulators can be operably linked to the promoters of the invention.
- Such cell cycle regulators include p27, pl6, p21, p57, pl8 , p73 , pl9, pl5, E2F-1, E2F-2, E2F-3, plO7, p 130 and E2F-4.
- cell cycle regulators include anti-angiogenic proteins, such as soluble Fltl (dominant negative soluble VEGF receptor), soluble Wnt receptors, soluble Tie2/Tek receptor, soluble hemopexin domain of matrix metalloprotease 2 and soluble receptors of other angiogenic cytokines (e.g., VEGFR1/KDR, VEGFR3/FU4, both VEGF receptors).
- anti-angiogenic proteins such as soluble Fltl (dominant negative soluble VEGF receptor), soluble Wnt receptors, soluble Tie2/Tek receptor, soluble hemopexin domain of matrix metalloprotease 2 and soluble receptors of other angiogenic cytokines (e.g., VEGFR1/KDR, VEGFR3/FU4, both VEGF receptors).
- nucleic acids operably linked to the promoters of the invention can encode inducers of apoptosis, such as Bax , Bak, BcI-Xs , Bad , Bim, Bik, Bid, Harakiri, Ad ElB, Bad, ICE-CED3 proteases, TRAIL, SARP-2 and apoptin.
- inducers of apoptosis such as Bax , Bak, BcI-Xs , Bad , Bim, Bik, Bid, Harakiri, Ad ElB, Bad, ICE-CED3 proteases, TRAIL, SARP-2 and apoptin.
- tumor suppressors may also be encoded in nucleic acids operably linked to the promoters of the present invention.
- Such tumor suppressors include, but are not limited to p53, pl6, CCAM, p21, pl5, BRCAl, BRCA2, IRF-I, PTEN (MMACl), RB, APC, DCC, NF-I, NF-2, WT- 1, MEN-I, MEN-II, zacl, p73, VHL, FCC, MCC, DBCCRl, DCP4 and p57.
- an antibody fragment or a single-chain antibody can be encoded in nucleic acids linked to the promoters of the invention.
- a single chain antibody is created by fusing together the variable domains of the heavy and light chains using a short peptide linker, thereby reconstituting an antigen binding site on a single molecule.
- Single-chain antibody variable fragments scFvs
- scFvs Single-chain antibody variable fragments in which the C-terminus of one variable domain is tethered to the N-terminus of the other via a 15 to 25 amino acid peptide or linker, have been developed without significantly disrupting antigen binding or specificity of the binding.
- These scFvs lack the constant regions (Fc) present in the heavy and light chains of the native antibody.
- Antibodies capable of binding to a wide variety of molecules are contemplated, including antibodies that bind SPANX polypeptides, as described herein. However, the antibodies and antibody fragments can bind to oncogenes, growth factors, hormones, enzymes, transcription factors, receptors viral proteins and the like. Also contemplated are secreted antibodies, targeted to serum, against angiogenic factors (VEGF/VSP, beta-FGF, alpha-FGF and others) and endothelial antigens necessary for angiogenesis (i.e., V3 integrin). Specifically contemplated are growth factors such as transforming growth factor and platelet derived growth factor.
- Oncogenes that are targets for such antibodies and/or antibody fragments include ras, myc, neu, raf, erb, src, fins, jun, trk , ret, hst, gsp, bcl-2 and abl. Also contemplated to be useful will be anti-apoptotic genes and angiogenesis promoters.
- cytolytic or oncolytic viral proteins may be encoded in a nucleic acid that is operably linked to a promoter of the invention. The cell will typically localize in a tumor microenvironment where the viral product is expressed by the promoter. In some cases, an entire viral genome may be expressed and the virus may infect the surrounding cells.
- the virus will selectively or preferentially lyse or kill hyperproliferative or tumor cells.
- Cytolytic or oncolytic viruses are known. Examples of oncolytic viruses include mutated adenovirus (Heise et al., Nat. Med., 3:639-645 (1997)), mutated vaccinia virus (Gnant et al., Cancer Res., 59:3396-3403 (1999)) and mutated reovirus (Coffey et al., Science, 282:1332- 1334 (1998)). Examples of viral vectors for use in gene therapy include mutated vaccinia vims (Lattime et al., Semin.
- any one particular construct or expression cassette that includes a promoter of the invention may be combined with any other construct or expression cassette, either in the same or different expression vector.
- Such “combined" therapies may have particular import in treating multiple aspects of condition, disease, or other abnonnal physiology, for example, when treating multidrug resistant (MDR) cancers.
- MDR multidrug resistant
- one aspect of the present invention utilizes a combination of expression cassettes, each encoding a beneficial gene product, wherein at least one of the gene products is operably linked to a promoter of the invention. This combination permits expression of the beneficial agent(s) in an appropriate site in a tissue, organ or organism for treatment of diseases, so that both agents can beneficially operate to optimally treat the disease.
- the present invention also relates to a process for treating cancer comprising operably linking a nucleic acid that encodes an anti-cancer or other beneficial gene product to a promoter of the invention such that expression of the anti-cancer or beneficial gene product suppresses the cancer.
- the promoter is selected from the group consisting of the sequences of SEQ ID NO:206-210.
- the anti-cancer or beneficial gene product is generally operably linked to an Nl promoter, for example, a promoter with SEQ ID NO:206.
- Nucleic acids that can inhibit the functioning of SPANX RNA include small interfering RNAs (siRNAs), ribozymes, antisense nucleic acids, and the like.
- prostate cancer can be treated by administering to a mammal a nucleic acid that can inhibit the functioning of an SPANX RNA.
- the nucleic acid that inhibits the function of SPANX-N mRNA can be operably linked to a SPANX-N promoter to generate an expression cassette useful for inhibiting production of SPANX-N polypeptides.
- Nucleic acids that can inhibit the function of an SPANX RNA can be generated from coding and non-coding regions of the SPANX gene.
- nucleic acids that can inhibit the function of an SPANX RNA are often selected to be complementary to sequences near the 5' end of the coding region of the RNA.
- the nucleic acid that can inhibit the functioning of an SPANX RNA can be complementary to a SPANX-N mRNA sequences encoded near the 5' end of SEQ ID NO:26 to 30.
- nucleic acids that can inhibit the function of an SPANX RNA can be complementary to a SPANX-A/D mRNA, for example, a mRNA encoded by any one of SEQ ID NO:31-35.
- nucleic acids that can inhibit the function of an SPANX RNA can be complementary to SPANX RNAs from other species (e.g., mouse, rat, cat, dog, goat, pig, gorilla or a monkey SPANX RNA).
- a nucleic acid that can inhibit the functioning of an SPANX RNA need not be 100% complementary to a selected region of mRNA. Instead, some variability in the sequence of the nucleic acid that can inhibit the functioning of an SPANX RNA is permitted.
- a nucleic acid that can inhibit the functioning of a human SPANX RNA can be complementary to a nucleic acid encoding a mouse or rat SPANX gene product. Nucleic acids encoding mouse SPANX gene product, for example, can be found in the NCBI database at GenBank.
- nucleic acids that can hybridize under moderately or highly stringent hybridization conditions are sufficiently complementary to inhibit the functioning of an SPANX RNA and can be utilized in the compositions of the invention.
- stringent hybridization conditions are selected to be about 5 0 C lower than the the ⁇ nal melting point (T m ) for the specific sequence at a defined ionic strength and pH.
- stringent conditions encompass temperatures in the range of about 1 0 C to about 2O 0 C lower than the the ⁇ nal pointing point of the selected sequence, depending upon the desired degree of stringency as otherwise qualified herein.
- the nucleic acids that can inhibit the functioning of SPANX RNA can hybridize to an SPANX RNA under physiological conditions, for example, physiological temperatures and salt concentrations.
- Inhibitory nucleic acid molecules that comprise, for example, 2, 3, 4, or 5 or more stretches of contiguous nucleotides that are precisely complementary to an SPANX coding sequence, each separated by a stretch of contiguous nucleotides that are not complementary to adjacent SPANX mRNA coding sequences, can inhibit the ⁇ function of SPANX mRNA.
- each stretch of contiguous nucleotides is at least 4, 5, 6, 7, or 8 or more nucleotides in length.
- Non-complementary intervening sequences are preferably 1, 2, 3, or 4 nucleotides in length.
- One skilled in the art can easily use the calculated melting point of a nucleic acid hybridized to a sense nucleic acid to estimate the degree of mismatching that will be tolerated between a particular nucleic acid for inhibiting expression of a particular SPANX RNA.
- a nucleic acid that can inhibit the function of an endogenous SPANX RNA is an anti-sense oligonucleotide.
- the anti-sense oligonucleotide is complementary to at least a portion of the sequence of a SPANX mRNA.
- Such anti-sense oligonucleotides are generally at least six nucleotides in length, but can be about 8, 12, 15, 20, 25, 30, 35, 40, 45, or 50 nucleotides long. Longer oligonucleotides can also be used.
- SPANX anti-sense oligonucleotides can be provided in a DNA construct, or expression cassette and introduced into cells introduced into tumor sites.
- ribozyme is an RNA molecule with catalytic activity. See, e.g., Cech, 1987, Science 236: 1532-1539; Cech, 1990, Ann. Rev. Biochem. 59:543-568; Cech, 1992, Curr. Opin. Struct. Biol. 2: 605-609; Couture and Stinchcomb, 1996, Trends Genet. 12: 510-515. Ribozymes can be used to inhibit gene function by cleaving an RNA sequence, as is known in the art (see, e.g., Haseloff et al., U.S. Pat. No. 5,641,673).
- SPANX nucleic acids complementary to mRNA encoded by any of SEQ ID NO:26-30 or SEQ ID NO:31-35 can be used to generate ribozymes that will specifically bind to mRNA transcribed from an SPANX gene.
- SPANX nucleic acids complementary to mRNA include those with sequence identity to the cDNA sequences of SEQ ID NO:26-30 or SEQ ID NO:31-35.
- the cleavage activity of ribozymes can be targeted to specific RNAs by engineering a discrete "hybridization" region into the ribozyme.
- the hybridization region contains a sequence complementary to the target RNA and thus specifically hybridizes with the target (see, for example, Gerlach et al., EP 321,201).
- the target sequence can be a segment of about 10, 12, 15, 20, or 50 contiguous nucleotides selected from a nucleotide sequence having SEQ ID NO:26-30 or SEQ ID NO:31-35. Longer complementary sequences can be used to increase the affinity of the hybridization sequence for the target.
- RNA interference involves post-transcriptional gene silencing
- siRNAs Small interfering RNAs
- siRNAs are generally 21-23 nucleotide dsRNAs that mediate post- transcriptional gene silencing.
- Introduction of siRNAs can induce post- transcriptional gene silencing in mammalian cells.
- siRNAs can also be produced in vivo by cleavage of dsRNA introduced directly or via a transgene or virus. Amplification by an RNA-dependent RNA polymerase may occur in some organisms.
- siRNAs are incorporated into the RNA-induced silencing complex, guiding the complex to the homologous endogenous mRNA where the complex cleaves the transcript. Rules for designing siRNAs are available. See, e.g., Elbashir SM,
- an effective siRNA can be made by selecting target sites within SEQ ID NO:26-35 that begin with AA, that have 3' UU overhangs for both the sense and antisense siRNA strands, and that have an approximate 50% G/C content.
- a siRNA of the invention for inhibiting SPANX-N mRNA functioning can have any of the following sequences:
- AACAGCCCAC UUCAAGCAUC AAUUU (SEQ IDNO:39) from SPANX-Nl.
- AAGCAUCAAU GGGGAGAAGA GGUUU (SEQ IDNO:40) from SPANX-Nl.
- AACUUCCAGC ACCAAUGGGG AGUUU (SEQIDNO-.44)fromSPANX-N3.
- AAGAGCCAAC UUCCAGCACC AAUUU (SEQ IDNO:45) from SPANX-N4.
- a siRNA of the invention for inhibiting SPANX-A/D mRNA functioning can have any of the following sequences:
- AAGAUUCAAA ACCUACAAAA GCCUUU (SEQ IDNO-.51) fromSPANX-A2.
- AACCUACAAA AGCCUGCCAC UUU (SEQ IDNO:52) from SPANX-A2.
- AAGAGCUCUG GGCCACUGCG AAG UUU (SEQ IDNO:53) from SPANX-Bl and SPANX-B2.
- AAGAUUCAAA AGCUCCAAAA ACCUUU SEQIDNO:55
- AAGCCUGCCG CAGACAUUGA AGUUU (SEQ IDNO:59)from SPANX-C.
- AAGCCUGCCG CUGACAUUGA AGUUU (SEQ IDNO:60) from SPANX-D.
- Nucleic acids that can decrease SPANX expression or translation can hybridize to an mRNA encoded by any one of SEQ ID NO:26-36 under physiological conditions. In other embodiments, these nucleic acids can hybridize to an mRNA encoded by a nucleic acid comprising SEQ ID NO:26-36 under stringent hybridization conditions. Examples of nucleic acids that can modulate the expression or translation of an SPANX polypeptide include a siRNA that consists essentially of a double-stranded RNA with any one of SEQ ID NO:39-61.
- the invention provides a method to identify an agent that modulates SPANX expression.
- the method involves contacting a test cell with a candidate agent and determining if the agent modulates SPANX expression, either by increasing or decreasing SPANX expression within the test cell.
- the invention provides a method for identify agents that increase or decrease SPANX expression.
- An increase or decrease in SPANX expression within a cell can be determined by comparing the SPANX expression within a test cell that was contacted with a candidate agent, with the SPANX expression within a control cell that was not contacted with a candidate agent.
- the SPANX expression in a control cell may be determined before, concurrently, or after the SPANX expression within the control cell is determined.
- SPANX expression can be determined by detecting activity of an
- SPANX promoter An increase or decrease in transcription from a SPANX promoter can be determined through use of many art recognized methods. For example, the presence and quantity of messenger RNA (mRNA) encoded by an SPANX regulated gene in a cell or other sample can be determined through use of hybridization based procedures, such as northern blotting, gene chip technologies, or through production and hybridization of complimentary DNA (cDNA). Additional examples of methods that can be used to detect and quantify mRNA of SPANX regulated genes include nucleic acid amplification based methods, such as polymerase chain reaction, ligase chain reaction, and the like. Instrumental methods may be used to detect and quantify mRNA of SPANX regulated genes.
- mRNA messenger RNA
- cDNA complimentary DNA
- probes containing a detectable label may be hybridized to the mRNA.
- Such probes may be labeled with a fluorescent tag that allows for rapid detection of the mRNA, and therefore provides for high- throughput screening of candidate agents that modulate SPANX expression.
- Such methods can be automated according to procedures in common practice in the pharmaceutical industry.
- Numerous labeled probes may be constructed, and include those that use fluorescence resonance energy transfer (FRET) or fluorescence quenching for detection.
- FRET fluorescence resonance energy transfer
- Such probes and instrumental methods are known in the art and have been reported (Sambrook et al., Molecular Cloning: A Laboratory Manual, 3rd edition. Cold Spring Harbor Press, Cold Spring Harbor, N. Y.
- Candidate agents can be identified that cause an increase or decrease in the transcription or translation of the gene encoding SPANX. Accordingly, a test cell can be contacted with a candidate agent. Production of SPANX mRNA or SPANX protein within the cell can be determined and compared to production in a control cell to determine if a candidate agent increases of decreases production of SPANX mRNA or protein. Such methods have been described herein and are known in the art.
- Antibodies have been described herein and can also be produced that bind to the SPANX protein. These antibodies can be used to determine if a candidate agent increases or decreases expression of the SPANX protein within a cell.
- the antibodies can be utilized in immunosorbant assays, such as enzyme-linked immunosorbant (ELIZA) or radio-immunosorbant assays (RIA), to detect SPANX protein.
- ELIZA enzyme-linked immunosorbant
- RIA radio-immunosorbant assays
- Test cells can also be constructed that express an SPANX protein that includes a tag.
- a fusion protein can be constructed such that the tag is an epitope that can be bound by an antibody (Shimada et al., Intemat. Immunol., 11:1357-1362 (1999)).
- An example of such a tag is the FLAG ® tag.
- An increase or decrease in the production of the fusion protein can then be readily followed through use of immunological techniques as are known in the art and described herein (Harlow et al., Antibodies: A Laboratory Manual, page 319 (Cold Spring Harbor Pub. 1988)).
- the antibodies, expression cassettes, expression vectors and nucleic acids of the invention, including their salts, are administered so as to achieve a reduction in at least one symptom associated with an indication or disease.
- the antibodies, expression cassettes, expression vectors and nucleic acids or combinations thereof may be administered as single or divided dosages, for example, of at least about 0.01 mg/kg to about 500 to 750 mg/kg, of at least about 0.01 mg/kg to about 300 to 500 mg/kg, at least about 0.1 mg/kg to about 100 to 300 mg/kg or at least about 1 mg/kg to about 50 to 100 mg/kg of body weight, although other dosages may provide beneficial results.
- the amount administered will vary depending on various factors including, but not limited to, the antibodies or nucleic acids chosen, the disease, the weight, the physical condition, the health, the age of the mammal, whether prevention or treatment is to be achieved.
- Administration of the therapeutic agents in accordance with the present invention may be in a single dose, in multiple doses, in a continuous or intermittent manner, depending, for example, upon the recipient's physiological condition, whether the purpose of the administration is therapeutic or prophylactic, and other factors known to skilled practitioners.
- the administration of the therapeutic agents of the invention may be essentially continuous over a pre-selected period of time or may be in a series of spaced doses. Both local and systemic administration is contemplated.
- therapeutic agents are synthesized or otherwise obtained, purified as necessary or desired and then lyophilized and stabilized.
- the therapeutic agents can then be adjusted to the appropriate concentration, and optionally combined with other agents.
- the absolute weight of a given antibody or nucleic acid included in a unit dose can vary widely. For example, about 0.01 to about 2 g, or about 0.1 to about 500 mg, of at least one
- the unit dosage can vary from about 0.01 g to about 50 g, from about 0.01 g to about 35 g, from about 0.1 g to about 25 g, from about 0.5 g to about 12 g, from about 0.5 g to about 8 g, from about 0.5 g to about 4 g, or from about 0.5 g to about 2 g.
- Daily doses of the therapeutic agents of the invention can vary as well. Such daily doses can range, for example, from about 0.1 g/day to about 50 g/day, from about 0.1 g/day to about 25 g/day, from about 0.1 g/day to about 12 g/day, from about 0.5 g/day to about 8 g/day, from about 0.5 g/day to about 4 g/day, and from about 0.5 g/day to about 2 g/day.
- one or more suitable unit dosage forms comprising the therapeutic agents of the invention can be administered by a variety of routes including oral, parenteral (including subcutaneous, intravenous, intramuscular and intraperitoneal), rectal, dermal, transdermal, intrathoracic, intrapulmonary and intranasal (respiratory) routes.
- the therapeutic agents may also be formulated for sustained release (for example, using microencapsulation, see WO 94/ 07529, and U.S. Patent No.4,962,091).
- the formulations may, where appropriate, be convenient ⁇ presented in discrete unit dosage forms and may be prepared by any of the methods well known to the pharmaceutical arts. Such methods may include the step of mixing the therapeutic agent with liquid earners, solid matrices, semi-solid carriers, finely divided solid carriers or combinations thereof, and then, if necessary, introducing or shaping the product into the desired delivery system.
- the therapeutic agents of the invention are prepared for oral administration, they are generally combined with a pharmaceutically acceptable carrier, diluent or excipient to form a pharmaceutical formulation, or unit dosage form.
- the therapeutic agents may be present as a powder, a granular formulation, a solution, a suspension, an emulsion or in a natural or synthetic polymer or resin for ingestion of the active ingredients from a chewing gum.
- the active ingredients may also be presented as a bolus, electuary or paste.
- Orally administered therapeutic agents of the invention can also be formulated for sustained release, e.g., the antibodies and/or nucleic acids can be coated, micro-encapsulated, or otherwise placed within a sustained delivery device.
- the total active ingredients in such formulations comprise from 0.1 to 99.9% by weight of the formulation.
- pharmaceutically acceptable it is meant a carrier, diluent, excipient, and/or salt that is compatible with the other ingredients of the formulation, and not deleterious to the recipient thereof.
- compositions containing the therapeutic agents of the invention can be prepared by procedures known in the art using well-known and readily available ingredients.
- the therapeutic agents can be formulated with common excipients, diluents, or carriers, and formed into tablets, capsules, solutions, suspensions, powders, aerosols and the like.
- excipients, diluents, and carriers that are suitable for such formulations include buffers, as well as fillers and extenders such as starch, cellulose, sugars, mannitol, and silicic derivatives.
- Binding agents can also be included such as carboxymethyl cellulose, hydroxymethylcellulose, hydroxypropyl methylcellulose and other cellulose derivatives, alginates, gelatin, and polyvinyl-pyrrolidone.
- Moisturizing agents can be included such as glycerol, disintegrating agents such as calcium carbonate and sodium bicarbonate.
- Agents for retarding dissolution can also be included such as paraffin.
- Resorption accelerators such as quaternary ammonium compounds can also be included.
- Surface active agents such as cetyl alcohol and glycerol monostearate can be included.
- Adsorptive carriers such as kaolin and bentonite can be added.
- Lubricants such as talc, calcium and magnesium stearate, and solid polyethyl glycols can also be included. Preservatives may also be added.
- the compositions of the invention can also contain thickening agents such as cellulose and/or cellulose derivatives. They may also contain gums such as xanthan, guar or carbo gum or gum arabic, or alternatively polyethylene glycols, bentones and montmorillonites, and the like.
- tablets or caplets containing the therapeutic agents of the invention can include buffering agents such as calcium carbonate, magnesium oxide and magnesium carbonate.
- Caplets and tablets can also include inactive ingredients such as cellulose, pre-gelatinized starch, silicon dioxide, hydroxy propyl methyl cellulose, magnesium stearate, microcrystalline cellulose, starch, talc, titanium dioxide, benzoic acid, citric acid, com starch, mineral oil, polypropylene glycol, sodium phosphate, zinc stearate, and the like.
- Hard or soft gelatin capsules containing at least one antibody or nucleic acid of the invention can contain inactive ingredients such as gelatin, microcrystalline cellulose, sodium lauryl sulfate, starch, talc, and titanium dioxide, and the like, as well as liquid vehicles such as polyethylene glycols (PEGs) and vegetable oil.
- inactive ingredients such as gelatin, microcrystalline cellulose, sodium lauryl sulfate, starch, talc, and titanium dioxide, and the like, as well as liquid vehicles such as polyethylene glycols (PEGs) and vegetable oil.
- PEGs polyethylene glycols
- enteric-coated caplets or tablets containing one or more antibodies or nucleic acids of the invention are designed to resist disintegration in the stomach and dissolve in the more neutral to alkaline environment of the duodenum.
- the therapeutic agents of the invention can also be formulated as elixirs or solutions for convenient oral administration or as solutions appropriate for parenteral administration, for instance by intramuscular, subcutaneous, intraperitoneal or intravenous routes.
- the pharmaceutical formulations of the therapeutic agents of the invention can also take the form of an aqueous or anhydrous solution or dispersion, or alternatively the form of an emulsion or suspension or salve.
- the therapeutic agents may be formulated for parenteral administration (e.g., by injection, for example, bolus injection or continuous infusion) and may be presented in unit dose form in ampoules, pre-filled syringes, small volume infusion containers or in multi-dose containers.
- preservatives can be added to help maintain the shelve life of the dosage form.
- the active agents and other ingredients may form suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
- the active agents and other ingredients may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilization from solution, for constitution with a suitable vehicle, e.g., sterile, pyrogen-free water, before use.
- formulations can contain pharmaceutically acceptable earners, vehicles and adjuvants that are well known in the art. It is possible, for example, to prepare solutions using one or more organic solvent(s) that is/ are acceptable from the physiological standpoint, chosen, in addition to water, from solvents such as acetone, ethanol, isopropyl alcohol, glycol ethers such as the products sold under the name "Dowanol,” polyglycols and polyethylene glycols, C1-C4 alkyl esters of short-chain acids, ethyl or isopropyl lactate, fatty acid triglycerides such as the products marketed under the name "Miglyol,” isopropyl myristate, animal, mineral and vegetable oils and polysiloxanes.
- solvents such as acetone, ethanol, isopropyl alcohol, glycol ethers such as the products sold under the name "Dowanol,” polyglycols and polyethylene glycols, C1-C4 alkyl esters of short-
- antioxidants chosen from antioxidants, surfactants, other preservatives, film-forming, keratolytic or comedolytic agents, perfumes, flavorings and colorings.
- Antioxidants such as t-butylhydroquinone, butylated hydroxyanis ⁇ le, butylated hydroxytoluene and ⁇ -tocopherol and its derivatives can be added.
- the therapeutic agents are well suited to formulation as sustained release dosage forms and the like.
- the formulations can be so constituted that they release the active agent, for example, in a particular part of the intestinal, urogenital or respiratory tract, possibly over a period of time.
- Coatings, envelopes, and protective matrices may be made, for example, from polymeric substances, such as polylactide-glycolates, liposomes, microemulsions, microparticles, nanoparticles, or waxes. These coatings, envelopes, and protective matrices are useful to coat indwelling devices, e.g., stents, catheters, peritoneal dialysis tubing, draining devices and the like.
- the therapeutic agents may be formulated as is known in the art for direct application to a target area.
- Forms chiefly conditioned for topical application take the form, for example, of creams, milks, gels, dispersion or microemulsions, lotions thickened to a greater or lesser extent, impregnated pads, ointments or sticks, aerosol formulations (e.g., sprays or foams), soaps, detergents, lotions or cakes of soap.
- Other conventional forms for this purpose include wound dressings, coated bandages or other polymer coverings, ointments, creams, lotions, pastes, jellies, sprays, and aerosols.
- the therapeutic agents of the invention can be delivered via patches or bandages for dermal administration.
- the therapeutic agents can be formulated to be part of an adhesive polymer, such as polyacrylate or acrylate/vinyl acetate copolymer.
- an adhesive polymer such as polyacrylate or acrylate/vinyl acetate copolymer.
- the backing layer can be any appropriate thickness that will provide the desired protective and support functions.
- a suitable thickness will generally be from about 10 to about 200 microns.
- Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents.
- Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilizing agents, dispersing agents, suspending agents, thickening agents, or coloring agents.
- the therapeutic agents can also be delivered via iontophoresis, e.g., as disclosed in U.S. Patent Nos. 4,140,122; 4,3S3,529; or 4,051,842.
- the percent by weight of a therapeutic agent of the invention present in a topical formulation will depend on various factors, but generally will be from 0.01% to 95% of the total weight of the formulation, and typically 0.1 -85% by weight.
- Drops such as eye drops or nose drops, may be formulated with one or more of the therapeutic agents in an aqueous or non-aqueous base also comprising one or more dispersing agents, solubilizing agents or suspending agents.
- Liquid sprays are conveniently delivered from pressurized packs. Drops can be delivered via a simple eye dropper-capped bottle, or via a plastic bottle adapted to deliver liquid contents dropwise, via a specially shaped closure.
- the therapeutic agents may further be formulated for topical administration in the mouth or throat.
- the active ingredients may be formulated as a lozenge further comprising a flavored base, usually sucrose and acacia or tragacanth; pastilles comprising the composition in an inert base such as gelatin and glycerin or sucrose and acacia; and mouthwashes comprising the composition of the present invention in a suitable liquid carrier.
- the pharmaceutical formulations of the present invention may include, as optional ingredients, pharmaceutically acceptable carriers, diluents, solubilizing or emulsifying agents, and salts of the type that are available in the art.
- pharmaceutically acceptable carriers such as physiologically buffered saline solutions and water.
- diluents such as phosphate buffered saline solutions pH 7.0-8.0.
- the therapeutic agents of the invention can also be administered to the respiratory tract.
- the present invention also provides aerosol pharmaceutical formulations and dosage forms for use in the methods of the invention.
- dosage forms comprise an amount of at least one of the agents of the invention effective to treat or prevent the clinical symptoms of a specific indication or disease. Any statistically significant attenuation of one or more symptoms of an indication or disease that has been treated pursuant to the method of the present invention is considered to be a treatment of such indication or disease within the scope of the invention.
- the composition may take the form of a dry powder, for example, a powder mix of the therapeutic agent and a suitable powder base such as lactose or starch.
- the powder composition may be presented in unit dosage form in, for example, capsules or cartridges, or, e.g., gelatin or blister packs from which the powder may be administered with the aid of an inhalator, insufflator, or a metered-dose inhaler (see, for example, the pressurized metered dose inhaler (MDI) and the dry powder inhaler disclosed in Newman, S. P. in Aerosols and the Lung.
- MDI pressurized metered dose inhaler
- the dry powder inhaler disclosed in Newman, S. P. in Aerosols and the Lung.
- Therapeutic agents of the present invention can also be administered in an aqueous solution when administered in an aerosol or inhaled form.
- other aerosol pharmaceutical fo ⁇ nulations may comprise, for example, a physiologically acceptable buffered saline solution containing between about 0.1 mg/ml and about 100 mg/ml of one or more of the agents of the present invention specific for the indication or disease to be treated.
- Dry aerosol in the form of finely divided solid antibody or nucleic acid particles that are not dissolved or suspended in a liquid are also useful in the practice of the present invention.
- Therapeutic agents of the present invention may be formulated as dusting powders and comprise finely divided particles having an average particle size of between about 1 and 5 ⁇ m, alternatively between 2 and 3 ⁇ m.
- Finely divided particles may be prepared by pulverization and screen filtration using techniques well known in the art.
- the particles may be administered by inhaling a predetermined quantity of the finely divided material, which can be in the form of a powder.
- the unit content of active ingredient or ingredients contained in an individual aerosol dose of each dosage form need not in itself constitute an effective amount for treating the particular indication or disease since the necessary effective amount can be reached by administration of a plurality of dosage units.
- the effective amount may be achieved using less than the dose in the dosage form, either individually, or in a series of administrations.
- the therapeutic agents of the invention are conveniently delivered from a nebulizer or a pressurized pack or other convenient means of delivering an aerosol spray.
- Pressurized packs may comprise a suitable propellant such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
- the dosage unit may be determined by providing a valve to deliver a metered amount.
- Nebulizers include, but are not limited to, those described in U.S. Patent Nos. 4,624,251; 3,703,173; 3,561,444; and 4,635,627.
- Aerosol delivery systems of the type disclosed herein are available from numerous commercial sources including Fisons Corporation (Bedford, Mass.), Schering Corp. (Kenilworth, NJ) and American Pharmoseal Co., (Valencia, CA).
- the therapeutic agent may also be administered via nose drops, a liquid spray, such as via a plastic bottle atomizer or metered-dose inhaler.
- atomizers are the Mistometer (Wintrop) and the Medihaler (Riker).
- the active ingredients may also be used in combination with other therapeutic agents, for example, pain relievers, anti-inflammatory agents, and the like, whether for the conditions described or some other condition.
- the present invention further pertains to a packaged pharmaceutical composition for controlling prostate cancer such as a kit or other container.
- the kit or container holds a therapeutically effective amount of a pharmaceutical composition for controlling prostate cancer and instructions for using the pharmaceutical composition for control of the prostate cancer.
- the pharmaceutical composition includes at least one antibody or nucleic acid of the present invention, in a therapeutically effective amount such that a prostate cancer is controlled.
- This Example describes the sequence, genomic organization and cellular expression patterns of SPANX-N genes. This Example also provides evidence that SPANX-Al, -A2, -B, -C and -D evolved from the SPANX-N genes.
- F2/ R2 5'-cattctcagtccatgtgga-3' (SEQ ID NO:78) 5'-gcaggctactcatgacacta-3' (SEQ ID NO:79)
- PrimSX-RR/ PrimSX-F5 5'-ctacctcttcccttcccttccttc-3' (SEQ ID NO:86) 5' tgggacactgcctgtatgat-3' (SEQ ID NO:87)
- PCR was performed by using 1 ⁇ l of genomic DNA (100 ng) in a 50 ⁇ l reaction volume under the following conditions: 94°C, 2 min (thirty cycles of 94 0 C, 30 s; 60 0 C, 10 s; 68°C, 9 min); 72°C, 7 min; 4°C, hold.
- RNAs from mouse (brain, testis, liver, and heart) and human (brain, testis, liver, and skeletal muscle) tissues were used for screening SPANX expression with the primers described in Table 1.
- Complementary DNA cDNA was made from 1 ⁇ g of total RNA using the Superscript first-strand system kit (Invitrogen) and priming with oligo(dT) pursuant to the manufacturer's standard protocol.
- Human ⁇ -actin primers (BD Biosciences Clontech) were used as positive controls for both human and mouse RT-PCR.
- NCI-60 cancer cell lines were from the National Cancer Institute.
- RT-PCR was performed by using 1 ⁇ l of cDNA or 1 ⁇ l of genomic DNA in a 50- ⁇ l reaction volume. Standard reaction conditions were as follows: 94 0 C, 5 min (35 cycles of 94°C, 1 min; 55 0 C, 1 min; 72 0 C, 1 min); 72 0 C, 7 min; and 4°C, hold.
- TAR cloning experiments were carried out as described in Kouprina, N. & Larionov, V. (2003) FEMS Microbiol. Rev. 27, 1-21.
- the TAR vector was constructed by using pVC604.
- the vector contained 5' 164-bp and 3' 187-bp targeting sequences, specific to the unique sequences flanking SPANX-C. These targeting sequences were amplified from human genomic DNA with specific primers (Table 1). The 5' and 3' targeting sequences correspond to positions 39,708-39,872 and 122,818- 123,004 in the bacterial artificial chromosome (BAC) (AL109799). Before use in TAR cloning experiments, the vector was linearized with SpIiI. Genomic DNAs were prepared from primate tissue culture lines (Coriell Institute for Medical Research). To identify clones positive for LDOCl, yeast transformants were examined by PCR by using a pair of diagnostic primers (Table 1).
- the yield of LDOCl -positive clones from African apes genomic DNAs was the same as with human DNA (1%).
- the size, AIu profiles, and retrofitting of yeast artificial chromosomes (YACs) into BACs were determined as described in Kouprina, N. & Larionov, V. (2003) FEMS Microbiol. Rev. 27, 1-21. AIu profiles of three independent TAR isolates for each species were indistinguishable. These results strongly suggest that the isolated YACs contain non-rearranged genomic segments.
- the human SPANX-Nl to -N5 gene sequences have accession numbers AY825029-AY825033.
- Protein secondary structure was predicted by using the PHD program (see website at cubic.bioc.columbia.edu/ predict protein), with a multiple sequence alignment submitted as a query. See, Rost, B., Sander, C. & Schneider, R. (1994) Comput. Appl. Biosci. 10, 53-60; website at cubic.bioc.columbia.edu/predict protein.
- the phylogenetic tree was constructed by using the neighbor-joining method (Saitou, N. & Nei, M. (1987) MoI. Biol, Evol.
- the SPANX Family Identification of a Second Subfamily in Primates and a Single SPANX Gene in Rodents.
- primate genomic segments homologous to human SPANX were isolated and characterized.
- the SPANX regions from five species (chimpanzee, gorilla, orangutan, rhesus macaque, and tamarin) were amplified by using a set of primers developed from the conserved 5' and 3' flanking sequences of human SPANX genes (see Materials and Methods).
- PCR products with a size predicted for the SPANX-A/D genes (1.2 kb) were obtained only from African apes (FIG. 1).
- Expansion and variability of exon 2 size are due to the presence of a 39-bp mini-satellite sequence at its 5' end. Similar amplification of mini-satellites in exons without disruption of the ORF has been previously described for other genes. See Yang et al. (2000) Am. J. Med. Genet. 95, 385- 390; Lievers et al. (2001) Eur. J. Hum. Genet. 9, 583-589. End sequencing of 9.0-kb primate clones revealed significant sequence similarity to exon 1 and exon 2 of the 1.4-kb clones. The 1.4- and 9.0-kb clones differed in that the latter contained a second LTR upstream of exon 2.
- the ERV-containing genes were classified as a second SPANX subfamily, which the inventors have named SPANX-N.
- the SPANX-N genes encode proteins with predicted polypeptide sequences of 72 amino acids (SPANX-Nl), 180 amino acids (SPANX-N2), 141 amino acids (SPANX-N3), 159 amino acids (SPANX-N4), and 72 amino acids (SPANX-Nl).
- a search of the GenBank database revealed two regions of significant similarity to human SPANX-N in the mouse and rat genomes. Both mouse and rat SPANX-N homologs are previously unannotated genes; the expression of the mouse gene was supported by the detection of eight ESTs in Database of Expressed Sequence Tags (dbEST) (BU939216, CA463062, CA464820, CB273391, BX635129, BC048649, CB273391, and BU946237).
- the mouse and rat gene encode, respectively, 87 amino acid and 115 amino acid proteins with 28-36% amino acid identity to human SPA NX-N genes.
- the mouse gene contains a 250-bp intron that shares about 65% identity with the primate SPANX intron.
- the smaller size of the intron is due to the absence of the ERV sequence or the LTR, which is present in all primate SPANX genes.
- This murine SPANX homolog appears to be a single murine ortholog of human SPANX-N 1-N4 because it shows the closest similarity to the SPANX-N genes and is located in the mouse chromosome X region syntenic to SPANX-N 1-N4.
- the SPANX- N subfamily is apparently represented not only in all primates but also in rodents, whereas the SPANX-A/D genes appear to be present exclusively in the African great apes and humans.
- the most prominent conserved sequence feature of the SPANX family is the central hydrophobic patch ending with an arginine. Secondary structure prediction suggested that the central conserved region formed a ⁇ -hairpin with a strongly hydrophobic proximal strand, followed by an ⁇ -helix. The rest of the protein seems to have a disordered structure with few residues conserved throughout the family but with considerable conservation within subfamilies and a marked preponderance of charged and polar residues.
- the bipartite nuclear localization signal that has been previously detected in the SPANX-AlD subfamily (Zendman et al. (2003) Gene 309, 125-133) is conserved in most of the SPANX-N proteins, with the exception of SPANX-N2 and -N4 but not in the rodent sequences; however, the latter contain a putative monopartite nuclear localization signal.
- the presence of a small globular core embedded in apparently disordered structure suggests that SPANX protein monomers may be unstable and is compatible with the reported dimer formation. See, Westbrook et al. (2001) Biol. Reprod. 64, 345-358; Westbrook et al. (2004) Clin. Cancer Res. 10, 101— 112.
- SPANX-N Genes are Expressed in Normal Testis and in Melanoma Cell Lines.
- expression of these genes was analyzed in a panel of normal tissues.
- a 264-bp band of expected size was detected only in testis (FIG. 3A).
- Sequencing of the RT-PCR products confirmed the identity of these transcripts to the SPANX-N2 and -N3 genes.
- the amplified sequences corresponded to two ESTs in dbEST (BU569937 and BF967778).
- Similar experiments with a panel of normal tissues from mice also detected expression of the mouse SPANX gene only in testis (FIG. 3B).
- the exclusive expression of these genes in normal testis correlated with the conservation of the promoter region, which contained two recognition sites for testis-specific transcription factors (FIG. S).
- SPANX-N expression was also examined in the NIH-60 panel of cancer cell lines that represent nine different types of cancers. See, Zendman et al. (2003) Gene 309, 125-133. RT-PCR products of SPANX-N2 or -N3 of the expected size were detected only in a melanoma cell line (Table 3).
- NSCLC non-small cell lung cancer
- *LOX IMVI cell line was derived from a malignant amelanotic melanoma.
- SPANX-AlD subfamily is also expressed in the same line.
- Co-expression of members of the two SPANX gene subfamilies is not surprising because of the remarkable conservation of the promoter sequences.
- expression profile analysis indicates that the SPANX-N subfamily, similar to the SPANX-AID subfamily, consists of cancer/testis antigens (CTA) genes.
- CTA cancer/testis antigens
- the rate of evolution of SPANX genes is outstanding even among reproductive proteins.
- the highest level of conservation between rodent SPANX proteins and human SPNAX-N family members is about 36%, substantially less than the values observed for most testis-associated proteins and about the same as for transition protein 2, the most rapid evolving among analyzed human and mouse orthologs. Makalowski, W. & Boguski, M. S. (1998) J. MoI. Evol. 47, 119-121; Swanson, W. J. & Vacquier, V. D. (2002) Nat. Rev. Genet. 3, 137— 144.
- the dalds ratio for SPANX genes was typically close to 1 (Table 4), which normally would be inteipreted as evolution under substantially relaxed purifying selection, perhaps near-neutral evolution.
- Table 5 Mean evolutionary distances for the '5 flanking regions, the intron, and the coding sequences of the SPAN-X genes.
- SPANX family One highly unusual feature of the SPANX family is that both synonymous and nonsynonymous positions in the coding sequences of many SPANX genes evolved much faster than the noncoding sequences of the 5' UTR and the intron (Tables 4 and 5). This anomalous mode of evolution was detected both among the closely related paralogs within the SPANX-AID and -N subfamilies and in intersub family comparisons. Most of the intron sequences do not seem to contain specific functional signals and are believed to evolve
- SPANX-N genes lacking the ERV and containing only a solo LTR in their intron apparently evolved independently in New World monkeys and great apes via duplications accompanied by homologous recombination between the ERVs LTRs.
- Other SPANX-N duplications left the ERV intact, as illustrated by the existence of four ERV-containing SPANX-N genes in humans (the exact number of such genes in apes and monkeys remains to be determined).
- the emergence of the SPANX-AID gene subfamily appears to be a more recent event, subsequent to the separation of the hominoid lineage from orangutan.
- this subfamily evolved via duplication of one of the SPANX-N genes accompanied by deletion of the distal part of exon 2 and rapid divergence (FIG. 4).
- the phylogenetic tree of the SPANX-A/D subfamily is most compatible with independent amplification of these genes in gorilla, chimpanzee, and humans (FIG. 5).
- the SPANX-C locus was chosen as a target. Because SPANX-C resides within an approximate 20-kb segmental duplication, the targeting sequences in the TAR vector were designed from unique sequences flanking SPANX-C. The vector efficiently clones an 83 -kb human genomic segment containing SPANX-C and LDOCl genes.
- SPANX-C flanking sequences The size difference is due to the absence of the 20-kb internal sequence containing the SPANX-C gene in African great apes. Partial sequencing of the chimpanzee clone revealed a similar organization of this syntenic region. Because this 20-kb sequence corresponds to a series of segmental duplications in chromosome X, it appears that at least the duplication that yielded SPANX-C occurred only in the human lineage (the alternative would require independent deletion of the same region in the gorilla, bonobo, and chimpanzee lineages, a highly unlikely event).
- S6 duplication is likely not polymorphic, because a SPANX-C null allele was not detected in a human population analysis that involved 200 individuals by PCR by using specifically designed primers (Table 2).
- a detailed sequence analysis of the gorilla TAR clone showed that its greater length, compared with the bonobo and chimpanzee sequence, was caused by a 3.4-kb insertion.
- This insertion contains an ORF homologous to several human ESTs (ALl 36558).
- the human gene corresponding to these ESTs consists of eight exons and spans about 30 kb on chromosome 3.
- the intron-less insert in gorilla appears to represent a reverse-transcribed duplication of this gene, most likely a retropseudogene.
- This Example provides genomic sequences for several SPANX-N genes, as well as information about where SPANX-N polypeptides are encoded in the genomic sequences.
- the SPANX-Nl genomic sequence (SEQ ID NO:92) is provided below.
- the SPANX-Nl polypeptide is encoded by nucleotides 119 to 253 and 8263 to 8406.
- SPANX-N2 genomic sequence (SEQ ID NO:93) is provided below.
- the SPANX-N2 polypeptide is encoded by nucleotides 179 to 256 and 8342 to 8806.
- SPANX-N3 genomic sequence (SEQ ID NO:94) is provided below.
- the SPANX-N3 polypeptide is encoded by nucleotides 179 to 256 and 8407 to
- SPANX-N4 genomic sequence (SEQ ID NO: 95) is provided below.
- the SPANX-N4 polypeptide is encoded by nucleotides ISl to 258 and 8191 to
- the SPANX-N5 genomic sequence (SEQ ID NO:96) is provided below.
- the SPANX-N5 polypeptide is encoded by nucleotides 174 to 248 and 891 to 1034.
- Prostate Cancer X-chromosome region DNA from these cell lines was used for PCR analysis. Genomic DNA from 40 normal individuals used as eligible controls (Caucasians) was purchased from Coriell Institute for Medical Research (Camden, NJ). Melanoma cell lines LoxMVI, 537 MEL 5 938 MEL and 888 MEL were obtained from the National Cancer Institute, NIH. Melanoma cell line VMMl 50 was derived from a tumor digest obtained from a patient at the
- RNA from normal adult human tissues prostate, placenta, proximal and distal colon, lung, and cervix
- matching normal/tumor tissue pairs Ambion, Austin, TX
- melanoma cell lines and primary uterine tumors was used for screening SPANX- N expression with the primers described in Table 9.
- Nlex2-F 5'-agggaagtgaatacaccaga-3" (SEQ ID NO:141)
- SeqN2ex2-F 5'-taacaggtgaccctacccat-3' (SEQ ID NO:143)
- N2ex2-F S'-tgagcgagtactccagaga-S' (SEQ ID NO:149) N2ex2-R 5'-ctggttgtgacgtactatact-3' (SEQ ID NO: 150) Sequencing
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002591918A CA2591918A1 (en) | 2004-12-15 | 2005-12-15 | Cancer-specific spanx-n markers |
AU2005316532A AU2005316532A1 (en) | 2004-12-15 | 2005-12-15 | Cancer-specific SPANX-N markers |
EP05854102A EP1838872A2 (en) | 2004-12-15 | 2005-12-15 | Cancer-specific spanx-n markers |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63681104P | 2004-12-15 | 2004-12-15 | |
US60/636,811 | 2004-12-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006065938A2 true WO2006065938A2 (en) | 2006-06-22 |
WO2006065938A3 WO2006065938A3 (en) | 2007-02-08 |
Family
ID=36588517
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/045317 WO2006065938A2 (en) | 2004-12-15 | 2005-12-15 | Cancer-specific spanx-n markers |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1838872A2 (en) |
AU (1) | AU2005316532A1 (en) |
CA (1) | CA2591918A1 (en) |
WO (1) | WO2006065938A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010084488A1 (en) | 2009-01-20 | 2010-07-29 | Ramot At Tel-Aviv University Ltd. | Mir-21 promoter driven targeted cancer therapy |
US8664183B2 (en) | 2009-02-27 | 2014-03-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | SPANX-B polypeptides and their use |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114262683B (en) * | 2022-03-01 | 2022-06-17 | 中国科学院动物研究所 | Bacterial preparation for expressing VEGFR 3D 2 polypeptide and construction method and application thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004020607A2 (en) * | 2002-08-30 | 2004-03-11 | Texas Tech University | SPAN-Xb GENE AND PROTEIN FOR THE DIAGNOSIS AND TREATMENT OF CANCER |
WO2004048518A2 (en) * | 2002-11-26 | 2004-06-10 | Incyte Corporation | Organelle-associated proteins |
-
2005
- 2005-12-15 EP EP05854102A patent/EP1838872A2/en not_active Withdrawn
- 2005-12-15 WO PCT/US2005/045317 patent/WO2006065938A2/en active Application Filing
- 2005-12-15 CA CA002591918A patent/CA2591918A1/en not_active Abandoned
- 2005-12-15 AU AU2005316532A patent/AU2005316532A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004020607A2 (en) * | 2002-08-30 | 2004-03-11 | Texas Tech University | SPAN-Xb GENE AND PROTEIN FOR THE DIAGNOSIS AND TREATMENT OF CANCER |
WO2004048518A2 (en) * | 2002-11-26 | 2004-06-10 | Incyte Corporation | Organelle-associated proteins |
Non-Patent Citations (5)
Title |
---|
DATABASE UniProt 7 December 2004 (2004-12-07), XP002394415 retrieved from EBI Database accession no. Q5VSR9 & KOUPRINA NATALAY ET AL: "The SPANX gene family of cancer/testis-specific antigens: Rapid evolution and amplification in African great apes and hominids." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 101, no. 9, 2 March 2004 (2004-03-02), pages 3077-3082, ISSN: 0027-8424 * |
HOPP T P ET AL: "PREDICTION OF PROTEIN ANTIGENIC DETERMINANTS FROM AMINO ACID SEQUENCES" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, NEW YORK, NY, US, vol. 78, no. 6, 1 June 1981 (1981-06-01), pages 3824-3828, XP000647365 * |
KOUPRINA NATALAY ET AL: "Dynamic structure of the SPANX gene cluster mapped to the prostate cancer susceptibility locus HPCX at Xq27" GENOME RESEARCH, vol. 15, no. 11, November 2005 (2005-11), pages 1477-1486, XP002394412 ISSN: 1088-9051 * |
WERNER THOMAS: "Target gene identification from expression array data by promoter analysis" BIOMOLECULAR ENGINEERING, vol. 17, no. 3, March 2001 (2001-03), pages 87-94, XP002394413 ISSN: 1389-0344 * |
ZENDMAN A J W ET AL: "The human SPANX multigene family: genomic organization, alignment and expression in male germ cells and tumor cell lines" GENE: AN INTERNATIONAL JOURNAL ON GENES AND GENOMES, ELSEVIER, AMSTERDAM, NL, vol. 309, no. 2, 8 May 2003 (2003-05-08), pages 125-133, XP004426689 ISSN: 0378-1119 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010084488A1 (en) | 2009-01-20 | 2010-07-29 | Ramot At Tel-Aviv University Ltd. | Mir-21 promoter driven targeted cancer therapy |
US8492133B2 (en) | 2009-01-20 | 2013-07-23 | Ramot At Tel Aviv University, Ltd. | MIR-21 promoter driven targeted cancer therapy |
US9044506B2 (en) | 2009-01-20 | 2015-06-02 | Alona Zilberberg | MIR-21 promoter driven targeted cancer therapy |
US8664183B2 (en) | 2009-02-27 | 2014-03-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | SPANX-B polypeptides and their use |
US9238684B2 (en) | 2009-02-27 | 2016-01-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | SPANX-B polypeptides and their use |
Also Published As
Publication number | Publication date |
---|---|
CA2591918A1 (en) | 2006-06-22 |
EP1838872A2 (en) | 2007-10-03 |
WO2006065938A3 (en) | 2007-02-08 |
AU2005316532A1 (en) | 2006-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2019201577B2 (en) | Cancer diagnostics using biomarkers | |
US7125663B2 (en) | Genes, compositions, kits and methods for identification, assessment, prevention, and therapy of cervical cancer | |
EP3062106B1 (en) | Method for determining androgen receptor variants in prostate cancer | |
US6165713A (en) | Composition and methods relating to DNA mismatch repair genes | |
CN101874120B (en) | Genetic variants on chr2 and chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment | |
KR20100017865A (en) | Genetic variants on chr 5p12 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment | |
KR20110081807A (en) | Genetic variants useful for risk assessment of thyroid cancer | |
US20060068411A1 (en) | Cancer specific gene MH15 | |
Darling et al. | Revertant mosaicism: partial correction of a germ-line mutation in COL17A1 by a frame-restoring mutation | |
AU2023202663A1 (en) | Hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) variants and uses thereof | |
US20070243176A1 (en) | Human genes and gene expression products | |
KR20100095564A (en) | Methods and compositions for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies | |
JP2018201515A (en) | MECP2E1 gene | |
KR20110015409A (en) | Gene expression markers for inflammatory bowel disease | |
JP2015109806A (en) | Method for detecting new ret fused body | |
US20050170500A1 (en) | Methods for identifying risk of melanoma and treatments thereof | |
US20030215803A1 (en) | Human genes and gene expression products isolated from human prostate | |
CN114182023A (en) | Detection kit and method for F-circP3F in rhabdomyosarcoma | |
WO2006065938A2 (en) | Cancer-specific spanx-n markers | |
DK2148932T3 (en) | SOX11 expression in malignant lymphomas | |
Müllenbach et al. | A novel discoidin domain receptor 1 (Ddr1) transcript is expressed in postmeiotic germ cells of the rat testis depending on the major histocompatibility complex haplotype | |
CN113832189B (en) | gRNA for knocking out pig immunoglobulin heavy chain IGHG region and application thereof | |
US20090011424A1 (en) | Cancer-suppressing agents | |
WO2007115068A2 (en) | Genetic variants in the indoleamine 2,3-dioxygenase gene | |
Nagai et al. | Down-regulation in human cancers of DRHC, a novel helicase-like gene from 17q25. 1 that inhibits cell growth |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2591918 Country of ref document: CA |
|
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005316532 Country of ref document: AU |
|
ENP | Entry into the national phase in: |
Ref document number: 2005316532 Country of ref document: AU Date of ref document: 20051215 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005316532 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005854102 Country of ref document: EP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 2005854102 Country of ref document: EP |